[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fj9U5a9oH6s-GPETZTV6W2VFCP0YS6L2vjklel16xGh4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"BeiGene",[4,6],"BeiGene USA, Inc.",135,false,26,23,22234,38,0,[15,18,21,24,26,29,31,33],{"name":16,"count":17},"Healthy Volunteers",11,{"name":19,"count":20},"Advanced Solid Tumor",8,{"name":22,"count":23},"Marginal Zone Lymphoma",6,{"name":25,"count":23},"Advanced Solid Tumors",{"name":27,"count":28},"Non-small Cell Lung Cancer",4,{"name":30,"count":28},"Non Small Cell Lung Cancer",{"name":32,"count":28},"Chronic Lymphocytic Leukemia",{"name":34,"count":28},"Small Lymphocytic Lymphoma",[36,41,46,51,56,61,65,69,74,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03336333","A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","2021-05-07","Zanubrutinib",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04379635","Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","2023-08-21","Tislelizumab",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05479994","Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","2025-01-24","BGB-11417",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05609370","A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer","2025-05-23","LBL-007",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05661955","A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.","2025-05-27","BGB-A445",{"nctId":62,"briefTitle":63,"date":64,"intervention":45},"NCT05909904","A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma","2025-06-17",{"nctId":66,"briefTitle":67,"date":68,"intervention":50},"NCT05471843","Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","2025-07-18",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06091943","Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer","2025-07-31","Tislelizumab IV",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04649385","BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors","2025-10-17","BGB-15025",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT03519230","Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","2025-12-01","Pamiparib",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,450,1121,1196,1259,1322,1352,1446,1472,1494,1512,1530,1548,1566,1584,1635,1665,1691,1722,1770,1808,1846,1872,1898,1927,1945,1963,1981,1999,2054,2076,2116,2139,2157,2175,2193,2211,2229,2247,2302,2345,2388,2422,2476,2502,2528,2550,2572,2594,2612,2630,2648,2666,2684,2702,2724,2758,2793,2815,2848,2866,2884,2902,2920,2938,2956,2974,2992,3010,3028,3046,3064,3094,3127,3149,3171,3205,3227,3249,3267,3291,3309,3327,3345,3363,3381,3399,3417,3435,3460,3478,3496,3514,3532,3555,3577,3595,3613,3631,3654,3672,3695],{"intervention":40,"totalTrials":93,"cells":94},32,{"EARLY_PHASE1":95,"PHASE1":97,"PHASE2":205,"PHASE3":375,"PHASE4":420,"NA":430},{"trials":96,"activeCount":13},[],{"trials":98,"activeCount":13},[99,111,122,131,143,153,162,171,182,195],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":109},"NCT04436107","Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma","COMPLETED",[86],"2024-03-28","2020-09-11",66,[108],"Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[40,110],"Lenalidomide",{"nctId":112,"briefTitle":113,"status":102,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":121},"NCT02795182","Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies",[86],"2020-12-18","2016-06-29",75,[119,120],"Lymphoma","Leukemia",[40,45],{"nctId":123,"briefTitle":124,"status":102,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":130},"NCT05547399","Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults",[86],"2022-12-07","2022-06-07",43,[16],[40],{"nctId":132,"briefTitle":133,"status":102,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":141},"NCT04470908","The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males",[86],"2020-11-10","2020-07-29",13,[139,140],"Healthy","Male",[40,142],"Rifabutin",{"nctId":144,"briefTitle":145,"status":102,"phases":146,"primaryCompletion":147,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":152},"NCT03189524","A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma",[86],"2020-08-26","2016-07-05",44,[151],"B-cell Lymphoma",[40],{"nctId":154,"briefTitle":155,"status":102,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":161},"NCT04163523","Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects",[86],"2016-07-21","2016-05-25",18,[16],[40],{"nctId":163,"briefTitle":164,"status":102,"phases":165,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":170},"NCT05767398","Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants",[86],"2023-04-28","2023-03-07",58,[16],[40],{"nctId":172,"briefTitle":173,"status":102,"phases":174,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT02569476","BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies",[86],"2020-09-02","2016-01-13",119,[179],"B-cell Lymphoid Malignancies",[40,181],"Obinutuzumab",{"nctId":183,"briefTitle":184,"status":102,"phases":185,"primaryCompletion":186,"completion":186,"start":187,"enrollment":9,"conditions":188,"interventions":190},"NCT04551963","Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies",[86],"2022-02-21","2020-11-15",[189],"B-cell Malignancies",[40,191,192,193,194],"Fluconazole","Diltiazem","Voriconazole","Clarithromycin",{"nctId":196,"briefTitle":197,"status":102,"phases":198,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},"NCT03465059","Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function",[86],"2018-10-19","2018-05-30",29,[203],"Hepatic Insufficiency & Healthy Subjects",[40],{"trials":206,"activeCount":374,"soonestReadout":333},[207,218,230,241,253,264,276,285,296,307,317,328,341,353,363],{"nctId":208,"briefTitle":209,"status":102,"phases":210,"primaryCompletion":211,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":217},"NCT04172246","Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies",[86,87],"2023-05-10","2025-06-30","2020-01-29",55,[216],"Mature B-cell Malignancies",[40],{"nctId":219,"briefTitle":220,"status":102,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":229},"NCT03206918","Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[87],"2018-06-15","2020-09-10","2017-03-09",91,[227,228],"Relapsed or Refractory Chronic Lymphocytic Leukemia","Relapsed or Refractory Small Lymphocytic Lymphoma",[40],{"nctId":231,"briefTitle":232,"status":102,"phases":233,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":240},"NCT03145064","Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed\u002FRefractory Non-GCB Type Diffuse Large B Cell Lymphoma",[87],"2019-05-24","2020-09-03","2017-06-30",41,[239],"Diffuse Large B-cell Lymphoma",[40],{"nctId":242,"briefTitle":243,"status":102,"phases":244,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":252},"NCT03206970","Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)",[87],"2019-02-15","2020-09-08","2017-03-02",86,[250,251],"Refractory Mantle Cell Lymphoma","Relapsed Mantle Cell Lymphoma",[40],{"nctId":254,"briefTitle":255,"status":102,"phases":256,"primaryCompletion":257,"completion":257,"start":258,"enrollment":237,"conditions":259,"interventions":262},"NCT03520920","BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)",[87],"2020-08-28","2018-01-04",[22,260,261],"Follicular Lymphoma","Diffuse Large B-Cell Lymphoma",[40,263],"Rituximab",{"nctId":265,"briefTitle":266,"status":102,"phases":267,"primaryCompletion":268,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":275},"NCT04116437","Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment",[87],"2026-01-09","2019-10-15",96,[272,273,22,274],"Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Mantle Cell Lymphoma","Waldenstrom Macroglobulinemia",[40],{"nctId":277,"briefTitle":278,"status":102,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":284},"NCT02343120","Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies",[86,87],"2021-03-31","2014-09-04",385,[189],[40],{"nctId":286,"briefTitle":287,"status":102,"phases":288,"primaryCompletion":289,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":295},"NCT05068440","Treatment of CD79B Mutant Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib",[87],"2025-03-31","2021-08-11",65,[293,294],"Relapsed Diffuse Large B-cell Lymphoma","Refractory Diffuse Large B-cell Lymphoma",[40],{"nctId":297,"briefTitle":298,"status":102,"phases":299,"primaryCompletion":300,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":306},"NCT04643470","Zanubrutinib in Participants With Active Proliferative Lupus Nephritis",[87],"2024-02-26","2024-08-26","2020-12-22",177,[305],"Lupus Nephritis",[40],{"nctId":308,"briefTitle":309,"status":102,"phases":310,"primaryCompletion":311,"completion":312,"start":313,"enrollment":149,"conditions":314,"interventions":316},"NCT03332173","Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed\u002FRefractory Waldenström's Macroglobulinemia (WM)",[87],"2019-05-08","2021-01-11","2017-08-31",[315],"Waldenström's Macroglobulinemia (WM)",[40],{"nctId":318,"briefTitle":319,"status":102,"phases":320,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":327},"NCT03332017","A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R\u002FR Follicular Lymphoma",[87],"2021-10-08","2024-12-27","2017-11-14",217,[326],"Relapsed\u002FRefractory Follicular Non-Hodgkin Lymphoma",[40,181],{"nctId":329,"briefTitle":330,"status":331,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT06697184","A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.","ACTIVE_NOT_RECRUITING",[86,87],"2027-06","2027-12-31","2025-01-23",56,[32,338],"CLL",[340,40],"Sonrotoclax",{"nctId":342,"briefTitle":343,"status":102,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":351},"NCT04382586","Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants",[87],"2021-02-01","2020-07-06",63,[349,350],"COVID-19 Pulmonary Complications","COVID-19",[40,352],"Supportive Care",{"nctId":354,"briefTitle":355,"status":102,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":362},"NCT03846427","Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma",[87],"2022-05-04","2019-02-19",68,[22,361],"MZL",[40],{"nctId":364,"briefTitle":365,"status":102,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":372},"NCT04282018","Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab",[86,87],"2024-08-28","2020-04-29",97,[32,34,260,22,273,371,19],"Diffuse Large B Cell Lymphoma",[373,40,45],"BGB-10188",1,{"trials":376,"activeCount":419,"soonestReadout":39},[377,386,396,407],{"nctId":37,"briefTitle":38,"status":331,"phases":378,"primaryCompletion":39,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":383},[88],"2027-10-31","2017-10-31",590,[32,34],[40,384,263,385],"Bendamustine","Venetoclax",{"nctId":387,"briefTitle":388,"status":331,"phases":389,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":395},"NCT04170283","Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies",[88],"2027-11","2028-12","2020-01-16",955,[189],[40,45],{"nctId":397,"briefTitle":398,"status":102,"phases":399,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":405},"NCT03734016","A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed\u002FRefractory Chronic Lymphocytic Leukemia",[88],"2022-08-08","2024-02-28","2018-11-01",652,[32,34],[40,406],"Ibrutinib",{"nctId":408,"briefTitle":409,"status":410,"phases":411,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":418},"NCT05100862","A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed\u002FRefractory Follicular or Marginal Zone Lymphoma","RECRUITING",[88],"2028-07","2030-06","2022-03-10",780,[417,22],"Relapsed\u002FRefractory Follicular Lymphoma",[40,263,110,181],3,{"trials":421,"activeCount":374,"soonestReadout":426},[422],{"nctId":423,"briefTitle":424,"status":410,"phases":425,"primaryCompletion":426,"completion":426,"start":77,"enrollment":159,"conditions":427,"interventions":429},"NCT07169331","A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia",[89],"2028-10-31",[428],"Waldenström's Macroglobulinemia",[40],{"trials":431,"activeCount":374,"soonestReadout":436},[432,442],{"nctId":433,"briefTitle":434,"status":410,"phases":435,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":441},"NCT05640102","Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia",[],"2026-12","2027-12","2023-03-03",111,[274],[40],{"nctId":443,"briefTitle":444,"status":445,"phases":446,"conditions":447,"interventions":449},"NCT04052854","A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies","NO_LONGER_AVAILABLE",[],[448],"Waldenström Macroglobulinemia",[40],{"intervention":45,"totalTrials":451,"cells":452},61,{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":588,"PHASE3":938,"PHASE4":1117,"NA":1119},{"trials":454,"activeCount":13},[],{"trials":456,"activeCount":587,"soonestReadout":77},[457,468,475,495,499,513,523,532,543,560,569,578],{"nctId":458,"briefTitle":459,"status":102,"phases":460,"primaryCompletion":49,"completion":49,"start":461,"enrollment":462,"conditions":463,"interventions":466},"NCT04215978","Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors",[86],"2020-01-30",204,[19,30,464,465],"Head and Neck Squamous Cell Carcinoma (HNSCC)","Nasopharyngeal Carcinoma (NPC)",[60,467],"tislelizumab",{"nctId":75,"briefTitle":76,"status":331,"phases":469,"primaryCompletion":77,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":474},[86],"2026-05-16","2021-03-04",157,[19],[78,45],{"nctId":476,"briefTitle":477,"status":102,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":484},"NCT04047862","Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors",[86],"2024-08-07","2019-08-15",446,[483],"Locally Advanced and Metastatic Solid Tumors",[485,45,486,487,488,489,490,491,492,493,494],"Ociperlimab","Pemetrexed","Paclitaxel","Nab paclitaxel","Carboplatin","Cisplatin","Etoposide","5fluorouracil","Oxaliplatin","Capecitabine",{"nctId":112,"briefTitle":113,"status":102,"phases":496,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":497,"interventions":498},[86],[119,120],[40,45],{"nctId":500,"briefTitle":501,"status":502,"phases":503,"primaryCompletion":268,"completion":268,"start":504,"enrollment":505,"conditions":506,"interventions":510},"NCT06540066","A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","TERMINATED",[86],"2024-09-11",35,[507,19,508,509],"Advanced Cancer","Metastatic Cancer","Metastatic Solid Tumor",[511,45,512],"BGB-B3227","Chemotherapy",{"nctId":514,"briefTitle":515,"status":502,"phases":516,"primaryCompletion":517,"completion":517,"start":518,"enrollment":214,"conditions":519,"interventions":521},"NCT05494762","Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors",[86],"2025-02-24","2022-08-25",[520],"Solid Tumor",[522,45],"BGB-B167",{"nctId":524,"briefTitle":525,"status":502,"phases":526,"primaryCompletion":527,"completion":527,"start":528,"enrollment":149,"conditions":529,"interventions":530},"NCT05904496","A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors",[86],"2025-08-20","2023-07-19",[25],[531,45],"BGB-30813",{"nctId":533,"briefTitle":534,"status":535,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":13,"conditions":540,"interventions":542},"NCT05644626","Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants","WITHDRAWN",[86],"2025-03","2025-08","2024-03",[541],"Solid Tumors",[522,45],{"nctId":544,"briefTitle":545,"status":410,"phases":546,"primaryCompletion":436,"completion":436,"start":547,"enrollment":548,"conditions":549,"interventions":557},"NCT06585488","A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification",[86],"2024-11-26",514,[550,551,552,553,554,555,556],"Metastatic Solid Tumors","Advanced Non-squamous Non-small-cell Lung Cancer","Advanced Colorectal Cancer","Advanced Pancreatic Ductal Adenocarcinoma","Advanced Gastric Cancer","Advanced Gastroesophageal Junction Cancer","Advanced Esophageal Adenocarcinoma",[558,45,559],"BGB-53038","Cetuximab",{"nctId":561,"briefTitle":562,"status":102,"phases":563,"primaryCompletion":564,"completion":564,"start":402,"enrollment":565,"conditions":566,"interventions":567},"NCT03666143","A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors",[86],"2023-01-05",216,[25],[568,45],"Sitravatinib",{"nctId":570,"briefTitle":571,"status":502,"phases":572,"primaryCompletion":573,"completion":573,"start":44,"enrollment":574,"conditions":575,"interventions":576},"NCT05935098","BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors",[86],"2026-01-27",99,[19,509,520],[577,45,512],"BGB-A3055",{"nctId":579,"briefTitle":580,"status":102,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":586},"NCT02660034","The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors",[86],"2020-09-09","2016-02-02",229,[541],[45,83],2,{"trials":589,"activeCount":937,"soonestReadout":54},[590,601,611,622,631,642,655,683,693,705,715,725,735,749,758,769,780,792,804,818,827,836,845,857,871,882,892,896,907,917,927],{"nctId":591,"briefTitle":592,"status":102,"phases":593,"primaryCompletion":594,"completion":595,"start":596,"enrollment":597,"conditions":598,"interventions":600},"NCT03419897","Study of BGB-A317 in Participants With Previously Treated Unresectable HCC",[87],"2021-06-30","2022-07-06","2018-04-09",249,[599],"Hepatocellular Carcinoma (HCC)",[45],{"nctId":602,"briefTitle":603,"status":102,"phases":604,"primaryCompletion":605,"completion":606,"start":280,"enrollment":607,"conditions":608,"interventions":610},"NCT04732494","Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma",[87],"2023-02-01","2023-12-26",125,[609],"Esophageal Squamous Cell Carcinoma",[45,485],{"nctId":612,"briefTitle":613,"status":410,"phases":614,"primaryCompletion":615,"completion":616,"start":617,"enrollment":618,"conditions":619,"interventions":621},"NCT03736889","Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors",[87],"2026-11","2027-09","2018-09-19",200,[620],"MSI-H\u002FdMMR Solid Tumors",[45],{"nctId":623,"briefTitle":624,"status":102,"phases":625,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":630},"NCT05267054","Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab",[86,87],"2024-08-30","2022-04-25",53,[293,294],[485,45,263],{"nctId":632,"briefTitle":633,"status":102,"phases":634,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":640},"NCT04952597","Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer",[87],"2023-07-26","2021-07-15",126,[639],"Limited Stage Small Cell Lung Cancer",[485,45,641],"Concurrent Chemoradiotherapy",{"nctId":643,"briefTitle":644,"status":102,"phases":645,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":653},"NCT06010303","A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma",[87],"2025-05-30","2026-05-07","2023-11-08",118,[651,609,652],"Esophageal Cancer","Esophageal Squamous Cell Carcinoma by AJCC V8 Stage",[55,45,654],"Chemotherapy Doublet",{"nctId":656,"briefTitle":657,"status":102,"phases":658,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":682},"NCT03493451","Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms",[87],"2021-04-21","2018-04-13",77,[663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680,681],"Peripheral T Cell Lymphoma","PTCL","Extranodal NK\u002FT-cell Lymphoma","Extranodal NK\u002FT-cell Lymphoma, Nasal Type","Extranodal NK T Cell Lymphoma","Extranodal NK T Cell Lymphoma, Nasal","Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Angioimmunoblastic T-Cell Lymphoma Recurrent","Angioimmunoblastic T-Cell Lymphoma Refractory","Peripheral T-cell Lymphoma NOS","Peripheral T-Cell Lymphoma, Not Otherwise Specified","Peripheral T-Cell Lymphoma Refractory","Anaplastic Large Cell Lymphoma","Anaplastic Large Cell Lymphoma, ALK-Positive","Anaplastic Large Cell Lymphoma, ALK-negative","ALK-negative Anaplastic Large Cell Lymphoma","ALK-Positive Anaplastic Large Cell Lymphoma","Cutaneous T-cell Lymphoma",[45],{"nctId":52,"briefTitle":53,"status":331,"phases":684,"primaryCompletion":54,"completion":685,"start":686,"enrollment":687,"conditions":688,"interventions":690},[86,87],"2026-12-31","2023-01-29",113,[689],"Unresectable or Metastatic Microsatellite Stable\u002FMismatch Repair Proficient Colorectal Cancer",[55,45,691,494,692],"Bevacizumab or Bevacizumab biosimilar","5-Fluorouracil",{"nctId":694,"briefTitle":695,"status":102,"phases":696,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":703},"NCT03432598","Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer",[87],"2019-02-25","2020-12-21","2017-08-24",54,[702],"Locally Advanced Lung Cancer; Metastatic Lung Cancer",[45,487,704,491,486,490,489],"Gemcitabine",{"nctId":706,"briefTitle":707,"status":102,"phases":708,"primaryCompletion":709,"completion":710,"start":711,"enrollment":687,"conditions":712,"interventions":714},"NCT04004221","Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer",[87],"2019-09-16","2021-03-11","2017-06-16",[713],"Locally Advanced or Metastatic Urothelial Bladder Cancer",[45],{"nctId":716,"briefTitle":717,"status":102,"phases":718,"primaryCompletion":719,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":724},"NCT04068519","Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody",[86,87],"2018-12-01","2020-05-31","2016-12-28",300,[25],[45],{"nctId":726,"briefTitle":727,"status":102,"phases":728,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":732,"interventions":733},"NCT04716634","Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors",[87],"2024-02-22","2021-04-19",84,[25],[45,734],"Fruquintinib",{"nctId":736,"briefTitle":737,"status":102,"phases":738,"primaryCompletion":739,"completion":739,"start":740,"enrollment":741,"conditions":742,"interventions":746},"NCT03744468","Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors",[86,87],"2025-02-06","2018-11-13",147,[743,744,745],"Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in","HNSCC for Phase 2 Dose Expansion","NSCLC for Phase 2 Dose Expansion",[747,45,748],"Surzebiclimab","Alcestobart",{"nctId":750,"briefTitle":751,"status":102,"phases":752,"primaryCompletion":753,"completion":335,"start":754,"enrollment":755,"conditions":756,"interventions":757},"NCT05577702","Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer",[87],"2024-12-13","2023-03-08",121,[30],[45,485,748,490,489,486,487],{"nctId":759,"briefTitle":760,"status":102,"phases":761,"primaryCompletion":762,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":768},"NCT04693234","AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer",[87],"2022-06-16","2023-08-31","2021-02-15",178,[767],"Cervical Cancer",[45,485],{"nctId":770,"briefTitle":771,"status":331,"phases":772,"primaryCompletion":773,"completion":774,"start":167,"enrollment":775,"conditions":776,"interventions":778},"NCT05635708","A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer",[87],"2025-12-31","2026-10",400,[27,777],"Metastatic Non-small Cell Lung Cancer",[45,60,55,489,490,779,487,488,78],"pemetrexed",{"nctId":781,"briefTitle":782,"status":102,"phases":783,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":791},"NCT05014815","Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer",[87],"2024-09-04","2021-11-16",272,[788,789,790],"Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)","Nonsmall Cell Lung Cancer, Stage IIIB","Nonsmall Cell Lung Cancer, Stage IV",[485,45,489,487,488,490,486],{"nctId":793,"briefTitle":794,"status":102,"phases":795,"primaryCompletion":796,"completion":797,"start":798,"enrollment":799,"conditions":800,"interventions":802},"NCT04974047","Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma",[87],"2023-04-17","2024-10-25","2021-08-17",70,[801],"Resectable Esophageal Squamous Cell Carcinoma",[45,487,490,803],"5-fluorouracil",{"nctId":805,"briefTitle":806,"status":102,"phases":807,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":812,"interventions":816},"NCT04401800","Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma",[87],"2022-12-01","2024-02-18","2020-09-04",64,[813,814,815],"Hepatocellular Carcinoma","Unresectable Hepatocellular Carcinoma","Metastatic Hepatocellular Carcinoma",[817,45],"Lenvatinib",{"nctId":57,"briefTitle":58,"status":331,"phases":819,"primaryCompletion":59,"completion":774,"start":820,"enrollment":687,"conditions":821,"interventions":826},[86,87],"2023-01-09",[822,823,824,825],"Urothelial Carcinoma","Renal Cell Carcinoma","Melanoma","Non-mucosal Melanoma",[60,45],{"nctId":828,"briefTitle":829,"status":502,"phases":830,"primaryCompletion":300,"completion":300,"start":831,"enrollment":270,"conditions":832,"interventions":833},"NCT05461794","Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma",[87],"2022-10-03",[609],[568,45,834,835],"Docetaxel","Irinotecan",{"nctId":837,"briefTitle":838,"status":102,"phases":839,"primaryCompletion":840,"completion":840,"start":841,"enrollment":799,"conditions":842,"interventions":844},"NCT03209973","A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma",[87],"2020-11-02","2017-04-21",[843],"Classical Hodgkin Lymphoma",[45],{"nctId":846,"briefTitle":847,"status":102,"phases":848,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":855},"NCT03469557","BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma",[87],"2019-03-31","2020-08-19","2017-07-18",30,[854],"Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma",[45,490,856,493,494],"5-FU",{"nctId":858,"briefTitle":859,"status":102,"phases":860,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":865,"interventions":869},"NCT04276493","Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With\u002FWithout Tislelizumab",[86,87],"2023-12-07","2024-10-31","2020-03-26",71,[866,867,868],"Breast Cancer","Gastric Cancer","Gastroesophageal Junction Cancer",[870,834,45,494,493],"Zanidatamab",{"nctId":872,"briefTitle":873,"status":102,"phases":874,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":878,"interventions":880},"NCT04948697","A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC",[87],"2024-02-01","2021-08-20",94,[879],"Advanced Hepatocellular Carcinoma",[485,45,881],"BAT1706",{"nctId":883,"briefTitle":884,"status":102,"phases":885,"primaryCompletion":886,"completion":887,"start":888,"enrollment":889,"conditions":890,"interventions":891},"NCT04318080","Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma",[87],"2022-12-12","2024-08-29","2020-08-20",46,[843],[45],{"nctId":364,"briefTitle":365,"status":102,"phases":893,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":894,"interventions":895},[86,87],[32,34,260,22,273,371,19],[373,40,45],{"nctId":897,"briefTitle":898,"status":102,"phases":899,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":904,"interventions":906},"NCT05116085","Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer",[87],"2023-09-26","2025-01-03","2022-01-26",33,[905],"Colorectal Cancer",[45],{"nctId":908,"briefTitle":909,"status":102,"phases":910,"primaryCompletion":911,"completion":912,"start":913,"enrollment":168,"conditions":914,"interventions":915},"NCT05014828","To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors",[87],"2023-10-20","2024-07-10","2021-09-18",[19],[916,45],"lenvatinib",{"nctId":62,"briefTitle":63,"status":331,"phases":918,"primaryCompletion":64,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":925},[87],"2026-05-28","2023-07-21",160,[923,924],"Head and Neck Squamous Cell Carcinoma","Head and Neck Cancer",[45,926,55],"BGB-A425",{"nctId":928,"briefTitle":929,"status":102,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":439,"conditions":933,"interventions":936},"NCT03941873","A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric\u002FGastroesophageal Junction Cancer",[86,87],"2023-03-31","2019-02-28",[934,935],"Carcinoma, Hepatocellular","Gastric\u002FGastroesophageal Junction Cancer",[568,45],5,{"trials":939,"activeCount":419,"soonestReadout":44},[940,949,960,969,973,985,995,1004,1015,1026,1035,1046,1057,1066,1076,1087,1096,1107],{"nctId":941,"briefTitle":942,"status":102,"phases":943,"primaryCompletion":636,"completion":944,"start":945,"enrollment":946,"conditions":947,"interventions":948},"NCT03358875","Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)",[88],"2024-01-18","2017-11-30",805,[27],[45,834],{"nctId":950,"briefTitle":951,"status":102,"phases":952,"primaryCompletion":953,"completion":954,"start":955,"enrollment":956,"conditions":957,"interventions":958},"NCT03412773","A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)",[88],"2022-07-11","2023-12-14","2017-12-18",684,[599],[45,959],"Sorafenib",{"nctId":42,"briefTitle":43,"status":331,"phases":961,"primaryCompletion":44,"completion":962,"start":963,"enrollment":964,"conditions":965,"interventions":966},[88],"2027-03-31","2020-05-29",453,[30],[45,490,487,967,968,489],"Pemetrexed Disodium","Placebos",{"nctId":387,"briefTitle":388,"status":331,"phases":970,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":971,"interventions":972},[88],[189],[40,45],{"nctId":974,"briefTitle":975,"status":102,"phases":976,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":981,"interventions":983},"NCT03783442","A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma",[88],"2022-02-28","2024-08-22","2018-12-11",649,[982],"Esophageal Squamous Cell Carcinoma (ESCC)",[490,493,984,494,487,45],"Fluorouracil",{"nctId":986,"briefTitle":987,"status":502,"phases":988,"primaryCompletion":989,"completion":989,"start":990,"enrollment":991,"conditions":992,"interventions":994},"NCT04921358","Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[88],"2023-12-20","2021-07-27",377,[993],"Non-Small Cell Lung Cancer (NSCLC)",[45,834,568],{"nctId":996,"briefTitle":997,"status":502,"phases":998,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":419,"conditions":1001,"interventions":1002},"NCT04486391","Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed\u002FRefractory Classical Hodgkin Lymphoma",[88],"2025-10-13","2020-12-14",[843],[45,1003],"Salvage Chemotherapy",{"nctId":1005,"briefTitle":1006,"status":502,"phases":1007,"primaryCompletion":646,"completion":1008,"start":1009,"enrollment":1010,"conditions":1011,"interventions":1013},"NCT04746924","A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer",[88],"2026-03-18","2021-05-24",669,[27,1012],"NSCLC",[45,485,1014],"Pembrolizumab",{"nctId":1016,"briefTitle":1017,"status":102,"phases":1018,"primaryCompletion":1019,"completion":1020,"start":1021,"enrollment":1022,"conditions":1023,"interventions":1025},"NCT03777657","Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma",[88],"2023-02-28","2024-08-27","2018-12-13",997,[1024],"Gastric, or Gastroesophageal Junction Adenocarcinoma",[45,490,493,494,692],{"nctId":1027,"briefTitle":1028,"status":535,"phases":1029,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":13,"conditions":1033,"interventions":1034},"NCT05564338","Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma",[88],"2027-04-30","2028-04-30","2023-06-30",[813],[568,45],{"nctId":1036,"briefTitle":1037,"status":331,"phases":1038,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":1043,"interventions":1044},"NCT03967977","Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma",[88],"2027-06-30","2027-10-21","2019-05-29",420,[822],[45,490,1045,489],"Gemcitabine Hydrochloride",{"nctId":1047,"briefTitle":1048,"status":102,"phases":1049,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1056},"NCT03663205","A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer",[88],"2020-01-23","2023-04-26","2018-07-23",334,[1055],"Non-Small Cell Lung Cancer",[45,490,489,486],{"nctId":1058,"briefTitle":1059,"status":102,"phases":1060,"primaryCompletion":1061,"completion":289,"start":1062,"enrollment":1063,"conditions":1064,"interventions":1065},"NCT03957590","A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma",[88],"2025-01-08","2019-06-11",370,[982],[45,487,490],{"nctId":1067,"briefTitle":1068,"status":102,"phases":1069,"primaryCompletion":1070,"completion":166,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1074},"NCT03594747","A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer",[88],"2020-09-30","2018-07-30",360,[1055],[45,487,1075,489],"Nab-paclitaxel",{"nctId":1077,"briefTitle":1078,"status":102,"phases":1079,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":1084,"interventions":1086},"NCT04005716","Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer",[88],"2023-04-19","2023-12-29","2019-07-22",457,[1085],"Small Cell Lung Cancer",[45,490,489,491],{"nctId":1088,"briefTitle":1089,"status":502,"phases":1090,"primaryCompletion":1091,"completion":1091,"start":1092,"enrollment":347,"conditions":1093,"interventions":1094},"NCT04866017","A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer",[88],"2023-10-17","2021-06-17",[30],[45,1095,485,512],"Durvalumab",{"nctId":1097,"briefTitle":1098,"status":102,"phases":1099,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":1104,"interventions":1106},"NCT03924986","Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)",[88],"2021-03-26","2023-12-08","2019-03-27",263,[1105],"Recurrent or Metastatic Nasopharyngeal Cancer",[45,704,490],{"nctId":1108,"briefTitle":1109,"status":102,"phases":1110,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1116},"NCT03430843","A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma",[88],"2020-12-01","2022-12-28","2018-01-26",512,[982],[45,487,834,835],{"trials":1118,"activeCount":13},[],{"trials":1120,"activeCount":13},[],{"intervention":490,"totalTrials":1122,"cells":1123},15,{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1132,"PHASE3":1158,"PHASE4":1192,"NA":1194},{"trials":1125,"activeCount":13},[],{"trials":1127,"activeCount":13},[1128],{"nctId":476,"briefTitle":477,"status":102,"phases":1129,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1130,"interventions":1131},[86],[483],[485,45,486,487,488,489,490,491,492,493,494],{"trials":1133,"activeCount":374,"soonestReadout":773},[1134,1138,1142,1146,1150,1154],{"nctId":694,"briefTitle":695,"status":102,"phases":1135,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":1136,"interventions":1137},[87],[702],[45,487,704,491,486,490,489],{"nctId":750,"briefTitle":751,"status":102,"phases":1139,"primaryCompletion":753,"completion":335,"start":754,"enrollment":755,"conditions":1140,"interventions":1141},[87],[30],[45,485,748,490,489,486,487],{"nctId":770,"briefTitle":771,"status":331,"phases":1143,"primaryCompletion":773,"completion":774,"start":167,"enrollment":775,"conditions":1144,"interventions":1145},[87],[27,777],[45,60,55,489,490,779,487,488,78],{"nctId":781,"briefTitle":782,"status":102,"phases":1147,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":1148,"interventions":1149},[87],[788,789,790],[485,45,489,487,488,490,486],{"nctId":793,"briefTitle":794,"status":102,"phases":1151,"primaryCompletion":796,"completion":797,"start":798,"enrollment":799,"conditions":1152,"interventions":1153},[87],[801],[45,487,490,803],{"nctId":846,"briefTitle":847,"status":102,"phases":1155,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":1156,"interventions":1157},[87],[854],[45,490,856,493,494],{"trials":1159,"activeCount":587,"soonestReadout":44},[1160,1164,1168,1172,1176,1180,1184,1188],{"nctId":42,"briefTitle":43,"status":331,"phases":1161,"primaryCompletion":44,"completion":962,"start":963,"enrollment":964,"conditions":1162,"interventions":1163},[88],[30],[45,490,487,967,968,489],{"nctId":974,"briefTitle":975,"status":102,"phases":1165,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":1166,"interventions":1167},[88],[982],[490,493,984,494,487,45],{"nctId":1016,"briefTitle":1017,"status":102,"phases":1169,"primaryCompletion":1019,"completion":1020,"start":1021,"enrollment":1022,"conditions":1170,"interventions":1171},[88],[1024],[45,490,493,494,692],{"nctId":1036,"briefTitle":1037,"status":331,"phases":1173,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":1174,"interventions":1175},[88],[822],[45,490,1045,489],{"nctId":1047,"briefTitle":1048,"status":102,"phases":1177,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":1053,"conditions":1178,"interventions":1179},[88],[1055],[45,490,489,486],{"nctId":1058,"briefTitle":1059,"status":102,"phases":1181,"primaryCompletion":1061,"completion":289,"start":1062,"enrollment":1063,"conditions":1182,"interventions":1183},[88],[982],[45,487,490],{"nctId":1077,"briefTitle":1078,"status":102,"phases":1185,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":1186,"interventions":1187},[88],[1085],[45,490,489,491],{"nctId":1097,"briefTitle":1098,"status":102,"phases":1189,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":1190,"interventions":1191},[88],[1105],[45,704,490],{"trials":1193,"activeCount":13},[],{"trials":1195,"activeCount":13},[],{"intervention":489,"totalTrials":17,"cells":1197},{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1215,"PHASE3":1233,"PHASE4":1255,"NA":1257},{"trials":1199,"activeCount":13},[],{"trials":1201,"activeCount":13},[1202,1206],{"nctId":476,"briefTitle":477,"status":102,"phases":1203,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1204,"interventions":1205},[86],[483],[485,45,486,487,488,489,490,491,492,493,494],{"nctId":1207,"briefTitle":1208,"status":502,"phases":1209,"primaryCompletion":1210,"completion":1210,"start":595,"enrollment":472,"conditions":1211,"interventions":1213},"NCT05381909","A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors",[86],"2025-07-25",[1212],"Solid Tumor, Adult",[1214,487,489,834],"BGB-24714",{"trials":1216,"activeCount":374,"soonestReadout":773},[1217,1221,1225,1229],{"nctId":694,"briefTitle":695,"status":102,"phases":1218,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":1219,"interventions":1220},[87],[702],[45,487,704,491,486,490,489],{"nctId":750,"briefTitle":751,"status":102,"phases":1222,"primaryCompletion":753,"completion":335,"start":754,"enrollment":755,"conditions":1223,"interventions":1224},[87],[30],[45,485,748,490,489,486,487],{"nctId":770,"briefTitle":771,"status":331,"phases":1226,"primaryCompletion":773,"completion":774,"start":167,"enrollment":775,"conditions":1227,"interventions":1228},[87],[27,777],[45,60,55,489,490,779,487,488,78],{"nctId":781,"briefTitle":782,"status":102,"phases":1230,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":1231,"interventions":1232},[87],[788,789,790],[485,45,489,487,488,490,486],{"trials":1234,"activeCount":587,"soonestReadout":44},[1235,1239,1243,1247,1251],{"nctId":42,"briefTitle":43,"status":331,"phases":1236,"primaryCompletion":44,"completion":962,"start":963,"enrollment":964,"conditions":1237,"interventions":1238},[88],[30],[45,490,487,967,968,489],{"nctId":1036,"briefTitle":1037,"status":331,"phases":1240,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":1241,"interventions":1242},[88],[822],[45,490,1045,489],{"nctId":1047,"briefTitle":1048,"status":102,"phases":1244,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":1053,"conditions":1245,"interventions":1246},[88],[1055],[45,490,489,486],{"nctId":1067,"briefTitle":1068,"status":102,"phases":1248,"primaryCompletion":1070,"completion":166,"start":1071,"enrollment":1072,"conditions":1249,"interventions":1250},[88],[1055],[45,487,1075,489],{"nctId":1077,"briefTitle":1078,"status":102,"phases":1252,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":1253,"interventions":1254},[88],[1085],[45,490,489,491],{"trials":1256,"activeCount":13},[],{"trials":1258,"activeCount":13},[],{"intervention":487,"totalTrials":1260,"cells":1261},12,{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1274,"PHASE3":1296,"PHASE4":1318,"NA":1320},{"trials":1263,"activeCount":13},[],{"trials":1265,"activeCount":13},[1266,1270],{"nctId":476,"briefTitle":477,"status":102,"phases":1267,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1268,"interventions":1269},[86],[483],[485,45,486,487,488,489,490,491,492,493,494],{"nctId":1207,"briefTitle":1208,"status":502,"phases":1271,"primaryCompletion":1210,"completion":1210,"start":595,"enrollment":472,"conditions":1272,"interventions":1273},[86],[1212],[1214,487,489,834],{"trials":1275,"activeCount":374,"soonestReadout":773},[1276,1280,1284,1288,1292],{"nctId":694,"briefTitle":695,"status":102,"phases":1277,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":1278,"interventions":1279},[87],[702],[45,487,704,491,486,490,489],{"nctId":750,"briefTitle":751,"status":102,"phases":1281,"primaryCompletion":753,"completion":335,"start":754,"enrollment":755,"conditions":1282,"interventions":1283},[87],[30],[45,485,748,490,489,486,487],{"nctId":770,"briefTitle":771,"status":331,"phases":1285,"primaryCompletion":773,"completion":774,"start":167,"enrollment":775,"conditions":1286,"interventions":1287},[87],[27,777],[45,60,55,489,490,779,487,488,78],{"nctId":781,"briefTitle":782,"status":102,"phases":1289,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":1290,"interventions":1291},[87],[788,789,790],[485,45,489,487,488,490,486],{"nctId":793,"briefTitle":794,"status":102,"phases":1293,"primaryCompletion":796,"completion":797,"start":798,"enrollment":799,"conditions":1294,"interventions":1295},[87],[801],[45,487,490,803],{"trials":1297,"activeCount":374,"soonestReadout":44},[1298,1302,1306,1310,1314],{"nctId":42,"briefTitle":43,"status":331,"phases":1299,"primaryCompletion":44,"completion":962,"start":963,"enrollment":964,"conditions":1300,"interventions":1301},[88],[30],[45,490,487,967,968,489],{"nctId":974,"briefTitle":975,"status":102,"phases":1303,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":1304,"interventions":1305},[88],[982],[490,493,984,494,487,45],{"nctId":1058,"briefTitle":1059,"status":102,"phases":1307,"primaryCompletion":1061,"completion":289,"start":1062,"enrollment":1063,"conditions":1308,"interventions":1309},[88],[982],[45,487,490],{"nctId":1067,"briefTitle":1068,"status":102,"phases":1311,"primaryCompletion":1070,"completion":166,"start":1071,"enrollment":1072,"conditions":1312,"interventions":1313},[88],[1055],[45,487,1075,489],{"nctId":1108,"briefTitle":1109,"status":102,"phases":1315,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":1316,"interventions":1317},[88],[982],[45,487,834,835],{"trials":1319,"activeCount":13},[],{"trials":1321,"activeCount":13},[],{"intervention":263,"totalTrials":28,"cells":1323},{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1338,"PHASE4":1348,"NA":1350},{"trials":1325,"activeCount":13},[],{"trials":1327,"activeCount":13},[],{"trials":1329,"activeCount":13},[1330,1334],{"nctId":623,"briefTitle":624,"status":102,"phases":1331,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":1332,"interventions":1333},[86,87],[293,294],[485,45,263],{"nctId":254,"briefTitle":255,"status":102,"phases":1335,"primaryCompletion":257,"completion":257,"start":258,"enrollment":237,"conditions":1336,"interventions":1337},[87],[22,260,261],[40,263],{"trials":1339,"activeCount":587,"soonestReadout":39},[1340,1344],{"nctId":37,"briefTitle":38,"status":331,"phases":1341,"primaryCompletion":39,"completion":379,"start":380,"enrollment":381,"conditions":1342,"interventions":1343},[88],[32,34],[40,384,263,385],{"nctId":408,"briefTitle":409,"status":410,"phases":1345,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":1346,"interventions":1347},[88],[417,22],[40,263,110,181],{"trials":1349,"activeCount":13},[],{"trials":1351,"activeCount":13},[],{"intervention":83,"totalTrials":20,"cells":1353},{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1387,"PHASE3":1432,"PHASE4":1442,"NA":1444},{"trials":1355,"activeCount":13},[],{"trials":1357,"activeCount":13},[1358,1369,1383],{"nctId":1359,"briefTitle":1360,"status":102,"phases":1361,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1367},"NCT03150810","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors",[86],"2023-05-04","2017-06-28",139,[1366],"Locally Advanced or Metastatic Solid Tumors",[83,1368],"Temozolomide",{"nctId":1370,"briefTitle":1371,"status":102,"phases":1372,"primaryCompletion":1373,"completion":1374,"start":1041,"enrollment":1375,"conditions":1376,"interventions":1377},"NCT03994211","Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer",[86],"2019-10-25","2021-08-06",25,[520],[1378,1379,1380,1381,1382],"pamiparib 60 mg","pamiparib 20 mg","itraconazole","rifampin","pamiparib",{"nctId":579,"briefTitle":580,"status":102,"phases":1384,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":1385,"interventions":1386},[86],[541],[45,83],{"trials":1388,"activeCount":13},[1389,1400,1410,1421],{"nctId":1390,"briefTitle":1391,"status":102,"phases":1392,"primaryCompletion":1393,"completion":1394,"start":1395,"enrollment":1396,"conditions":1397,"interventions":1399},"NCT03427814","Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer",[87],"2020-06-18","2023-01-03","2018-07-03",136,[1398],"Advanced or Inoperable Gastric Cancer",[83],{"nctId":1401,"briefTitle":1402,"status":502,"phases":1403,"primaryCompletion":1404,"completion":175,"start":1405,"enrollment":137,"conditions":1406,"interventions":1409},"NCT03712930","Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency",[87],"2020-08-06","2019-02-05",[1407,1408],"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Homologous Recombination Deficiency (HRD)",[83],{"nctId":1411,"briefTitle":1412,"status":102,"phases":1413,"primaryCompletion":1414,"completion":290,"start":1415,"enrollment":1416,"conditions":1417,"interventions":1420},"NCT03333915","Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors",[86,87],"2020-08-24","2016-12-21",128,[1418,1419],"Advanced High-grade Ovarian Cancer","Triple Negative Breast Cancer",[83],{"nctId":1422,"briefTitle":1423,"status":102,"phases":1424,"primaryCompletion":1425,"completion":1425,"start":1426,"enrollment":1427,"conditions":1428,"interventions":1430},"NCT03150862","A Study Assessing Pamiparib With Radiation and\u002For Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma",[86,87],"2021-03-17","2017-07-24",116,[1429],"Brain and Central Nervous System Tumors",[83,1431],"TMZ",{"trials":1433,"activeCount":374,"soonestReadout":82},[1434],{"nctId":80,"briefTitle":81,"status":331,"phases":1435,"primaryCompletion":82,"completion":1436,"start":1437,"enrollment":1438,"conditions":1439,"interventions":1441},[88],"2027-01-30","2018-05-14",224,[1440],"Ovarian Cancer",[83],{"trials":1443,"activeCount":13},[],{"trials":1445,"activeCount":13},[],{"intervention":181,"totalTrials":419,"cells":1447},{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1456,"PHASE3":1462,"PHASE4":1468,"NA":1470},{"trials":1449,"activeCount":13},[],{"trials":1451,"activeCount":13},[1452],{"nctId":172,"briefTitle":173,"status":102,"phases":1453,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":1454,"interventions":1455},[86],[179],[40,181],{"trials":1457,"activeCount":13},[1458],{"nctId":318,"briefTitle":319,"status":102,"phases":1459,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":1460,"interventions":1461},[87],[326],[40,181],{"trials":1463,"activeCount":374,"soonestReadout":412},[1464],{"nctId":408,"briefTitle":409,"status":410,"phases":1465,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":1466,"interventions":1467},[88],[417,22],[40,263,110,181],{"trials":1469,"activeCount":13},[],{"trials":1471,"activeCount":13},[],{"intervention":110,"totalTrials":587,"cells":1473},{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1482,"PHASE3":1484,"PHASE4":1490,"NA":1492},{"trials":1475,"activeCount":13},[],{"trials":1477,"activeCount":13},[1478],{"nctId":100,"briefTitle":101,"status":102,"phases":1479,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":1480,"interventions":1481},[86],[108],[40,110],{"trials":1483,"activeCount":13},[],{"trials":1485,"activeCount":374,"soonestReadout":412},[1486],{"nctId":408,"briefTitle":409,"status":410,"phases":1487,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":1488,"interventions":1489},[88],[417,22],[40,263,110,181],{"trials":1491,"activeCount":13},[],{"trials":1493,"activeCount":13},[],{"intervention":384,"totalTrials":374,"cells":1495},{"EARLY_PHASE1":1496,"PHASE1":1498,"PHASE2":1500,"PHASE3":1502,"PHASE4":1508,"NA":1510},{"trials":1497,"activeCount":13},[],{"trials":1499,"activeCount":13},[],{"trials":1501,"activeCount":13},[],{"trials":1503,"activeCount":374,"soonestReadout":39},[1504],{"nctId":37,"briefTitle":38,"status":331,"phases":1505,"primaryCompletion":39,"completion":379,"start":380,"enrollment":381,"conditions":1506,"interventions":1507},[88],[32,34],[40,384,263,385],{"trials":1509,"activeCount":13},[],{"trials":1511,"activeCount":13},[],{"intervention":385,"totalTrials":374,"cells":1513},{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1520,"PHASE4":1526,"NA":1528},{"trials":1515,"activeCount":13},[],{"trials":1517,"activeCount":13},[],{"trials":1519,"activeCount":13},[],{"trials":1521,"activeCount":374,"soonestReadout":39},[1522],{"nctId":37,"briefTitle":38,"status":331,"phases":1523,"primaryCompletion":39,"completion":379,"start":380,"enrollment":381,"conditions":1524,"interventions":1525},[88],[32,34],[40,384,263,385],{"trials":1527,"activeCount":13},[],{"trials":1529,"activeCount":13},[],{"intervention":967,"totalTrials":374,"cells":1531},{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1538,"PHASE4":1544,"NA":1546},{"trials":1533,"activeCount":13},[],{"trials":1535,"activeCount":13},[],{"trials":1537,"activeCount":13},[],{"trials":1539,"activeCount":374,"soonestReadout":44},[1540],{"nctId":42,"briefTitle":43,"status":331,"phases":1541,"primaryCompletion":44,"completion":962,"start":963,"enrollment":964,"conditions":1542,"interventions":1543},[88],[30],[45,490,487,967,968,489],{"trials":1545,"activeCount":13},[],{"trials":1547,"activeCount":13},[],{"intervention":968,"totalTrials":374,"cells":1549},{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1562,"NA":1564},{"trials":1551,"activeCount":13},[],{"trials":1553,"activeCount":13},[],{"trials":1555,"activeCount":13},[],{"trials":1557,"activeCount":374,"soonestReadout":44},[1558],{"nctId":42,"briefTitle":43,"status":331,"phases":1559,"primaryCompletion":44,"completion":962,"start":963,"enrollment":964,"conditions":1560,"interventions":1561},[88],[30],[45,490,487,967,968,489],{"trials":1563,"activeCount":13},[],{"trials":1565,"activeCount":13},[],{"intervention":1045,"totalTrials":374,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1574,"PHASE4":1580,"NA":1582},{"trials":1569,"activeCount":13},[],{"trials":1571,"activeCount":13},[],{"trials":1573,"activeCount":13},[],{"trials":1575,"activeCount":374,"soonestReadout":1039},[1576],{"nctId":1036,"briefTitle":1037,"status":331,"phases":1577,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":1578,"interventions":1579},[88],[822],[45,490,1045,489],{"trials":1581,"activeCount":13},[],{"trials":1583,"activeCount":13},[],{"intervention":50,"totalTrials":28,"cells":1585},{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1598,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1587,"activeCount":13},[],{"trials":1589,"activeCount":374,"soonestReadout":1594},[1590],{"nctId":1591,"briefTitle":1592,"status":331,"phases":1593,"primaryCompletion":1594,"completion":1594,"start":1595,"enrollment":811,"conditions":1596,"interventions":1597},"NCT04883957","Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies",[86],"2026-06","2021-07-05",[216],[50],{"trials":1599,"activeCount":419,"soonestReadout":49},[1600,1613,1622],{"nctId":1601,"briefTitle":1602,"status":410,"phases":1603,"primaryCompletion":1604,"completion":1604,"start":1009,"enrollment":1605,"conditions":1606,"interventions":1610},"NCT04771130","A Study of BGB-11417 in Participants With Myeloid Malignancies",[86,87],"2028-02-08",260,[1607,1608,1609],"Acute Myeloid Leukemia","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasm",[50,1611,1612,50,50],"Azacitidine","Posaconazole",{"nctId":47,"briefTitle":48,"status":331,"phases":1614,"primaryCompletion":49,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1621},[87],"2027-08-25","2022-10-25",100,[120,119,1619,34,1620],"Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Relapsed Chronic Lymphocytic Leukemia",[50],{"nctId":66,"briefTitle":67,"status":331,"phases":1623,"primaryCompletion":68,"completion":1624,"start":1625,"enrollment":607,"conditions":1626,"interventions":1628},[86,87],"2027-01-31","2022-09-05",[273,1627,251],"Refractory Mantle Cell Lymphoma (MCL)",[50],{"trials":1630,"activeCount":13},[],{"trials":1632,"activeCount":13},[],{"trials":1634,"activeCount":13},[],{"intervention":55,"totalTrials":28,"cells":1636},{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1641,"PHASE3":1659,"PHASE4":1661,"NA":1663},{"trials":1638,"activeCount":13},[],{"trials":1640,"activeCount":13},[],{"trials":1642,"activeCount":419,"soonestReadout":54},[1643,1647,1651,1655],{"nctId":643,"briefTitle":644,"status":102,"phases":1644,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":1645,"interventions":1646},[87],[651,609,652],[55,45,654],{"nctId":52,"briefTitle":53,"status":331,"phases":1648,"primaryCompletion":54,"completion":685,"start":686,"enrollment":687,"conditions":1649,"interventions":1650},[86,87],[689],[55,45,691,494,692],{"nctId":770,"briefTitle":771,"status":331,"phases":1652,"primaryCompletion":773,"completion":774,"start":167,"enrollment":775,"conditions":1653,"interventions":1654},[87],[27,777],[45,60,55,489,490,779,487,488,78],{"nctId":62,"briefTitle":63,"status":331,"phases":1656,"primaryCompletion":64,"completion":919,"start":920,"enrollment":921,"conditions":1657,"interventions":1658},[87],[923,924],[45,926,55],{"trials":1660,"activeCount":13},[],{"trials":1662,"activeCount":13},[],{"trials":1664,"activeCount":13},[],{"intervention":60,"totalTrials":419,"cells":1666},{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1675,"PHASE3":1685,"PHASE4":1687,"NA":1689},{"trials":1668,"activeCount":13},[],{"trials":1670,"activeCount":13},[1671],{"nctId":458,"briefTitle":459,"status":102,"phases":1672,"primaryCompletion":49,"completion":49,"start":461,"enrollment":462,"conditions":1673,"interventions":1674},[86],[19,30,464,465],[60,467],{"trials":1676,"activeCount":587,"soonestReadout":59},[1677,1681],{"nctId":770,"briefTitle":771,"status":331,"phases":1678,"primaryCompletion":773,"completion":774,"start":167,"enrollment":775,"conditions":1679,"interventions":1680},[87],[27,777],[45,60,55,489,490,779,487,488,78],{"nctId":57,"briefTitle":58,"status":331,"phases":1682,"primaryCompletion":59,"completion":774,"start":820,"enrollment":687,"conditions":1683,"interventions":1684},[86,87],[822,823,824,825],[60,45],{"trials":1686,"activeCount":13},[],{"trials":1688,"activeCount":13},[],{"trials":1690,"activeCount":13},[],{"intervention":78,"totalTrials":419,"cells":1692},{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1701,"PHASE3":1716,"PHASE4":1718,"NA":1720},{"trials":1694,"activeCount":13},[],{"trials":1696,"activeCount":374,"soonestReadout":77},[1697],{"nctId":75,"briefTitle":76,"status":331,"phases":1698,"primaryCompletion":77,"completion":470,"start":471,"enrollment":472,"conditions":1699,"interventions":1700},[86],[19],[78,45],{"trials":1702,"activeCount":374,"soonestReadout":773},[1703,1712],{"nctId":1704,"briefTitle":1705,"status":102,"phases":1706,"primaryCompletion":1707,"completion":1707,"start":1708,"enrollment":505,"conditions":1709,"interventions":1710},"NCT06029127","A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer",[87],"2024-12-31","2023-10-23",[1055],[1711,834,78],"Gimistotug",{"nctId":770,"briefTitle":771,"status":331,"phases":1713,"primaryCompletion":773,"completion":774,"start":167,"enrollment":775,"conditions":1714,"interventions":1715},[87],[27,777],[45,60,55,489,490,779,487,488,78],{"trials":1717,"activeCount":13},[],{"trials":1719,"activeCount":13},[],{"trials":1721,"activeCount":13},[],{"intervention":1723,"totalTrials":419,"cells":1724},"BGB-16673",{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1749,"PHASE3":1764,"PHASE4":1766,"NA":1768},{"trials":1726,"activeCount":13},[],{"trials":1728,"activeCount":374,"soonestReadout":1733},[1729,1739],{"nctId":1730,"briefTitle":1731,"status":331,"phases":1732,"primaryCompletion":1733,"completion":1733,"start":1734,"enrollment":1735,"conditions":1736,"interventions":1738},"NCT07005713","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria",[86],"2026-04-17","2025-07-19",34,[1737],"Chronic Spontaneous Urticaria",[1723],{"nctId":1740,"briefTitle":1741,"status":102,"phases":1742,"primaryCompletion":999,"completion":999,"start":1743,"enrollment":1744,"conditions":1745,"interventions":1746},"NCT06906809","Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants",[86],"2025-04-03",37,[16],[1723,1747,1748],"Itraconazole","Phenytoin",{"trials":1750,"activeCount":374,"soonestReadout":1755},[1751],{"nctId":1752,"briefTitle":1753,"status":410,"phases":1754,"primaryCompletion":1755,"completion":1755,"start":1756,"enrollment":1757,"conditions":1758,"interventions":1763},"NCT05294731","Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader",[86,87],"2029-01-31","2022-05-06",146,[1759,1760,273,272,448,22,260,1761,1762],"B-cell Malignancy","Non-Hodgkin Lymphoma","DLBCL Unclassifiable","Richter's Transformation",[1723],{"trials":1765,"activeCount":13},[],{"trials":1767,"activeCount":13},[],{"trials":1769,"activeCount":13},[],{"intervention":486,"totalTrials":23,"cells":1771},{"EARLY_PHASE1":1772,"PHASE1":1774,"PHASE2":1780,"PHASE3":1798,"PHASE4":1804,"NA":1806},{"trials":1773,"activeCount":13},[],{"trials":1775,"activeCount":13},[1776],{"nctId":476,"briefTitle":477,"status":102,"phases":1777,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1778,"interventions":1779},[86],[483],[485,45,486,487,488,489,490,491,492,493,494],{"trials":1781,"activeCount":374,"soonestReadout":773},[1782,1786,1790,1794],{"nctId":694,"briefTitle":695,"status":102,"phases":1783,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":1784,"interventions":1785},[87],[702],[45,487,704,491,486,490,489],{"nctId":750,"briefTitle":751,"status":102,"phases":1787,"primaryCompletion":753,"completion":335,"start":754,"enrollment":755,"conditions":1788,"interventions":1789},[87],[30],[45,485,748,490,489,486,487],{"nctId":770,"briefTitle":771,"status":331,"phases":1791,"primaryCompletion":773,"completion":774,"start":167,"enrollment":775,"conditions":1792,"interventions":1793},[87],[27,777],[45,60,55,489,490,779,487,488,78],{"nctId":781,"briefTitle":782,"status":102,"phases":1795,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":1796,"interventions":1797},[87],[788,789,790],[485,45,489,487,488,490,486],{"trials":1799,"activeCount":13},[1800],{"nctId":1047,"briefTitle":1048,"status":102,"phases":1801,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":1053,"conditions":1802,"interventions":1803},[88],[1055],[45,490,489,486],{"trials":1805,"activeCount":13},[],{"trials":1807,"activeCount":13},[],{"intervention":494,"totalTrials":23,"cells":1809},{"EARLY_PHASE1":1810,"PHASE1":1812,"PHASE2":1818,"PHASE3":1832,"PHASE4":1842,"NA":1844},{"trials":1811,"activeCount":13},[],{"trials":1813,"activeCount":13},[1814],{"nctId":476,"briefTitle":477,"status":102,"phases":1815,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1816,"interventions":1817},[86],[483],[485,45,486,487,488,489,490,491,492,493,494],{"trials":1819,"activeCount":374,"soonestReadout":54},[1820,1824,1828],{"nctId":52,"briefTitle":53,"status":331,"phases":1821,"primaryCompletion":54,"completion":685,"start":686,"enrollment":687,"conditions":1822,"interventions":1823},[86,87],[689],[55,45,691,494,692],{"nctId":846,"briefTitle":847,"status":102,"phases":1825,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":1826,"interventions":1827},[87],[854],[45,490,856,493,494],{"nctId":858,"briefTitle":859,"status":102,"phases":1829,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":1830,"interventions":1831},[86,87],[866,867,868],[870,834,45,494,493],{"trials":1833,"activeCount":13},[1834,1838],{"nctId":974,"briefTitle":975,"status":102,"phases":1835,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":1836,"interventions":1837},[88],[982],[490,493,984,494,487,45],{"nctId":1016,"briefTitle":1017,"status":102,"phases":1839,"primaryCompletion":1019,"completion":1020,"start":1021,"enrollment":1022,"conditions":1840,"interventions":1841},[88],[1024],[45,490,493,494,692],{"trials":1843,"activeCount":13},[],{"trials":1845,"activeCount":13},[],{"intervention":692,"totalTrials":419,"cells":1847},{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1862,"PHASE4":1868,"NA":1870},{"trials":1849,"activeCount":13},[],{"trials":1851,"activeCount":13},[],{"trials":1853,"activeCount":374,"soonestReadout":54},[1854,1858],{"nctId":52,"briefTitle":53,"status":331,"phases":1855,"primaryCompletion":54,"completion":685,"start":686,"enrollment":687,"conditions":1856,"interventions":1857},[86,87],[689],[55,45,691,494,692],{"nctId":793,"briefTitle":794,"status":102,"phases":1859,"primaryCompletion":796,"completion":797,"start":798,"enrollment":799,"conditions":1860,"interventions":1861},[87],[801],[45,487,490,803],{"trials":1863,"activeCount":13},[1864],{"nctId":1016,"briefTitle":1017,"status":102,"phases":1865,"primaryCompletion":1019,"completion":1020,"start":1021,"enrollment":1022,"conditions":1866,"interventions":1867},[88],[1024],[45,490,493,494,692],{"trials":1869,"activeCount":13},[],{"trials":1871,"activeCount":13},[],{"intervention":488,"totalTrials":419,"cells":1873},{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1882,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1875,"activeCount":13},[],{"trials":1877,"activeCount":13},[1878],{"nctId":476,"briefTitle":477,"status":102,"phases":1879,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1880,"interventions":1881},[86],[483],[485,45,486,487,488,489,490,491,492,493,494],{"trials":1883,"activeCount":374,"soonestReadout":773},[1884,1888],{"nctId":770,"briefTitle":771,"status":331,"phases":1885,"primaryCompletion":773,"completion":774,"start":167,"enrollment":775,"conditions":1886,"interventions":1887},[87],[27,777],[45,60,55,489,490,779,487,488,78],{"nctId":781,"briefTitle":782,"status":102,"phases":1889,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":1890,"interventions":1891},[87],[788,789,790],[485,45,489,487,488,490,486],{"trials":1893,"activeCount":13},[],{"trials":1895,"activeCount":13},[],{"trials":1897,"activeCount":13},[],{"intervention":1899,"totalTrials":587,"cells":1900},"sonrotoclax",{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1915,"PHASE3":1921,"PHASE4":1923,"NA":1925},{"trials":1902,"activeCount":13},[],{"trials":1904,"activeCount":13},[1905],{"nctId":1906,"briefTitle":1907,"status":102,"phases":1908,"primaryCompletion":1909,"completion":1910,"start":1911,"enrollment":852,"conditions":1912,"interventions":1914},"NCT06543043","A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers",[86],"2024-10-08","2024-11-07","2024-08-19",[1913],"Not Determined",[1748,1747,1899],{"trials":1916,"activeCount":374,"soonestReadout":333},[1917],{"nctId":329,"briefTitle":330,"status":331,"phases":1918,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":1919,"interventions":1920},[86,87],[32,338],[340,40],{"trials":1922,"activeCount":13},[],{"trials":1924,"activeCount":13},[],{"trials":1926,"activeCount":13},[],{"intervention":691,"totalTrials":374,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1939,"PHASE4":1941,"NA":1943},{"trials":1930,"activeCount":13},[],{"trials":1932,"activeCount":13},[],{"trials":1934,"activeCount":374,"soonestReadout":54},[1935],{"nctId":52,"briefTitle":53,"status":331,"phases":1936,"primaryCompletion":54,"completion":685,"start":686,"enrollment":687,"conditions":1937,"interventions":1938},[86,87],[689],[55,45,691,494,692],{"trials":1940,"activeCount":13},[],{"trials":1942,"activeCount":13},[],{"trials":1944,"activeCount":13},[],{"intervention":1611,"totalTrials":374,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1948,"activeCount":13},[],{"trials":1950,"activeCount":13},[],{"trials":1952,"activeCount":374,"soonestReadout":1604},[1953],{"nctId":1601,"briefTitle":1602,"status":410,"phases":1954,"primaryCompletion":1604,"completion":1604,"start":1009,"enrollment":1605,"conditions":1955,"interventions":1956},[86,87],[1607,1608,1609],[50,1611,1612,50,50],{"trials":1958,"activeCount":13},[],{"trials":1960,"activeCount":13},[],{"trials":1962,"activeCount":13},[],{"intervention":1612,"totalTrials":374,"cells":1964},{"EARLY_PHASE1":1965,"PHASE1":1967,"PHASE2":1969,"PHASE3":1975,"PHASE4":1977,"NA":1979},{"trials":1966,"activeCount":13},[],{"trials":1968,"activeCount":13},[],{"trials":1970,"activeCount":374,"soonestReadout":1604},[1971],{"nctId":1601,"briefTitle":1602,"status":410,"phases":1972,"primaryCompletion":1604,"completion":1604,"start":1009,"enrollment":1605,"conditions":1973,"interventions":1974},[86,87],[1607,1608,1609],[50,1611,1612,50,50],{"trials":1976,"activeCount":13},[],{"trials":1978,"activeCount":13},[],{"trials":1980,"activeCount":13},[],{"intervention":926,"totalTrials":374,"cells":1982},{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1993,"PHASE4":1995,"NA":1997},{"trials":1984,"activeCount":13},[],{"trials":1986,"activeCount":13},[],{"trials":1988,"activeCount":374,"soonestReadout":64},[1989],{"nctId":62,"briefTitle":63,"status":331,"phases":1990,"primaryCompletion":64,"completion":919,"start":920,"enrollment":921,"conditions":1991,"interventions":1992},[87],[923,924],[45,926,55],{"trials":1994,"activeCount":13},[],{"trials":1996,"activeCount":13},[],{"trials":1998,"activeCount":13},[],{"intervention":2000,"totalTrials":419,"cells":2001},"BGB-43395",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2046,"PHASE3":2048,"PHASE4":2050,"NA":2052},{"trials":2003,"activeCount":13},[],{"trials":2005,"activeCount":587,"soonestReadout":2010},[2006,2021,2037],{"nctId":2007,"briefTitle":2008,"status":331,"phases":2009,"primaryCompletion":2010,"completion":2011,"start":2012,"enrollment":903,"conditions":2013,"interventions":2018},"NCT06253195","BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+\u002FHER2- Breast Cancer and Other Advanced Solid Tumors",[86],"2026-02-28","2026-10-26","2024-04-01",[19,509,2014,866,2015,2016,2017],"Hormone-receptor-positive Breast Cancer","Metastatic Breast Cancer","Hormone Receptor Positive Malignant Neoplasm of Breast","HER2-negative Breast Cancer",[2000,2019,2020],"Fulvestrant","Letrozole",{"nctId":2022,"briefTitle":2023,"status":331,"phases":2024,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":2028,"interventions":2035},"NCT06257264","A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors",[86],"2026-08-31","2024-03-11",103,[866,1085,1440,867,2014,2029,19,2030,2031,2032,2033,2034],"Hormone Receptor Positive HER-2 Negative Breast Cancer","Endometrial Cancer","Prostate Cancer","TNBC - Triple-Negative Breast Cancer","GastroEsophageal Cancer","Bladder Cancer",[2036,2019,2000],"BG-68501",{"nctId":2038,"briefTitle":2039,"status":102,"phases":2040,"primaryCompletion":2041,"completion":2041,"start":2042,"enrollment":2043,"conditions":2044,"interventions":2045},"NCT06761898","A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants",[86],"2025-05-20","2025-01-14",51,[16],[2000,2000],{"trials":2047,"activeCount":13},[],{"trials":2049,"activeCount":13},[],{"trials":2051,"activeCount":13},[],{"trials":2053,"activeCount":13},[],{"intervention":2019,"totalTrials":587,"cells":2055},{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2068,"PHASE3":2070,"PHASE4":2072,"NA":2074},{"trials":2057,"activeCount":13},[],{"trials":2059,"activeCount":587,"soonestReadout":2010},[2060,2064],{"nctId":2007,"briefTitle":2008,"status":331,"phases":2061,"primaryCompletion":2010,"completion":2011,"start":2012,"enrollment":903,"conditions":2062,"interventions":2063},[86],[19,509,2014,866,2015,2016,2017],[2000,2019,2020],{"nctId":2022,"briefTitle":2023,"status":331,"phases":2065,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":2066,"interventions":2067},[86],[866,1085,1440,867,2014,2029,19,2030,2031,2032,2033,2034],[2036,2019,2000],{"trials":2069,"activeCount":13},[],{"trials":2071,"activeCount":13},[],{"trials":2073,"activeCount":13},[],{"trials":2075,"activeCount":13},[],{"intervention":2077,"totalTrials":587,"cells":2078},"BGB-45035",{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2098,"PHASE3":2110,"PHASE4":2112,"NA":2114},{"trials":2080,"activeCount":13},[],{"trials":2082,"activeCount":374,"soonestReadout":2087},[2083],{"nctId":2084,"briefTitle":2085,"status":410,"phases":2086,"primaryCompletion":2087,"completion":2087,"start":2088,"enrollment":2089,"conditions":2090,"interventions":2097},"NCT06342713","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases",[86],"2026-05-23","2024-06-20",211,[2091,2092,16,2093,2094,2095,2096],"Healthy Participants","Healthy Subjects","Autoimmune Diseases","Healthy Adult Participants","Atopic Dermatitis","Prurigo Nodularis",[2077],{"trials":2099,"activeCount":13},[2100],{"nctId":2101,"briefTitle":2102,"status":502,"phases":2103,"primaryCompletion":2104,"completion":2104,"start":2105,"enrollment":2106,"conditions":2107,"interventions":2109},"NCT07100938","A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis",[87],"2026-05-12","2025-08-21",49,[2108],"Rheumatoid Arthritis",[2077],{"trials":2111,"activeCount":13},[],{"trials":2113,"activeCount":13},[],{"trials":2115,"activeCount":13},[],{"intervention":73,"totalTrials":374,"cells":2117},{"EARLY_PHASE1":2118,"PHASE1":2120,"PHASE2":2131,"PHASE3":2133,"PHASE4":2135,"NA":2137},{"trials":2119,"activeCount":13},[],{"trials":2121,"activeCount":374,"soonestReadout":72},[2122],{"nctId":70,"briefTitle":71,"status":331,"phases":2123,"primaryCompletion":72,"completion":2124,"start":2125,"enrollment":2126,"conditions":2127,"interventions":2128},[86],"2026-07-31","2023-11-16",62,[27],[73,2129,2130],"Tislelizumab SC","Histology-Based Chemotherapy Doublet",{"trials":2132,"activeCount":13},[],{"trials":2134,"activeCount":13},[],{"trials":2136,"activeCount":13},[],{"trials":2138,"activeCount":13},[],{"intervention":2129,"totalTrials":374,"cells":2140},{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2149,"PHASE3":2151,"PHASE4":2153,"NA":2155},{"trials":2142,"activeCount":13},[],{"trials":2144,"activeCount":374,"soonestReadout":72},[2145],{"nctId":70,"briefTitle":71,"status":331,"phases":2146,"primaryCompletion":72,"completion":2124,"start":2125,"enrollment":2126,"conditions":2147,"interventions":2148},[86],[27],[73,2129,2130],{"trials":2150,"activeCount":13},[],{"trials":2152,"activeCount":13},[],{"trials":2154,"activeCount":13},[],{"trials":2156,"activeCount":13},[],{"intervention":2130,"totalTrials":374,"cells":2158},{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2167,"PHASE3":2169,"PHASE4":2171,"NA":2173},{"trials":2160,"activeCount":13},[],{"trials":2162,"activeCount":374,"soonestReadout":72},[2163],{"nctId":70,"briefTitle":71,"status":331,"phases":2164,"primaryCompletion":72,"completion":2124,"start":2125,"enrollment":2126,"conditions":2165,"interventions":2166},[86],[27],[73,2129,2130],{"trials":2168,"activeCount":13},[],{"trials":2170,"activeCount":13},[],{"trials":2172,"activeCount":13},[],{"trials":2174,"activeCount":13},[],{"intervention":2020,"totalTrials":374,"cells":2176},{"EARLY_PHASE1":2177,"PHASE1":2179,"PHASE2":2185,"PHASE3":2187,"PHASE4":2189,"NA":2191},{"trials":2178,"activeCount":13},[],{"trials":2180,"activeCount":374,"soonestReadout":2010},[2181],{"nctId":2007,"briefTitle":2008,"status":331,"phases":2182,"primaryCompletion":2010,"completion":2011,"start":2012,"enrollment":903,"conditions":2183,"interventions":2184},[86],[19,509,2014,866,2015,2016,2017],[2000,2019,2020],{"trials":2186,"activeCount":13},[],{"trials":2188,"activeCount":13},[],{"trials":2190,"activeCount":13},[],{"trials":2192,"activeCount":13},[],{"intervention":558,"totalTrials":374,"cells":2194},{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2203,"PHASE3":2205,"PHASE4":2207,"NA":2209},{"trials":2196,"activeCount":13},[],{"trials":2198,"activeCount":374,"soonestReadout":436},[2199],{"nctId":544,"briefTitle":545,"status":410,"phases":2200,"primaryCompletion":436,"completion":436,"start":547,"enrollment":548,"conditions":2201,"interventions":2202},[86],[550,551,552,553,554,555,556],[558,45,559],{"trials":2204,"activeCount":13},[],{"trials":2206,"activeCount":13},[],{"trials":2208,"activeCount":13},[],{"trials":2210,"activeCount":13},[],{"intervention":559,"totalTrials":374,"cells":2212},{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2221,"PHASE3":2223,"PHASE4":2225,"NA":2227},{"trials":2214,"activeCount":13},[],{"trials":2216,"activeCount":374,"soonestReadout":436},[2217],{"nctId":544,"briefTitle":545,"status":410,"phases":2218,"primaryCompletion":436,"completion":436,"start":547,"enrollment":548,"conditions":2219,"interventions":2220},[86],[550,551,552,553,554,555,556],[558,45,559],{"trials":2222,"activeCount":13},[],{"trials":2224,"activeCount":13},[],{"trials":2226,"activeCount":13},[],{"trials":2228,"activeCount":13},[],{"intervention":2036,"totalTrials":374,"cells":2230},{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2239,"PHASE3":2241,"PHASE4":2243,"NA":2245},{"trials":2232,"activeCount":13},[],{"trials":2234,"activeCount":374,"soonestReadout":2025},[2235],{"nctId":2022,"briefTitle":2023,"status":331,"phases":2236,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":2237,"interventions":2238},[86],[866,1085,1440,867,2014,2029,19,2030,2031,2032,2033,2034],[2036,2019,2000],{"trials":2240,"activeCount":13},[],{"trials":2242,"activeCount":13},[],{"trials":2244,"activeCount":13},[],{"trials":2246,"activeCount":13},[],{"intervention":485,"totalTrials":2248,"cells":2249},10,{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2258,"PHASE3":2288,"PHASE4":2298,"NA":2300},{"trials":2251,"activeCount":13},[],{"trials":2253,"activeCount":13},[2254],{"nctId":476,"briefTitle":477,"status":102,"phases":2255,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":2256,"interventions":2257},[86],[483],[485,45,486,487,488,489,490,491,492,493,494],{"trials":2259,"activeCount":13},[2260,2264,2268,2272,2276,2280,2284],{"nctId":602,"briefTitle":603,"status":102,"phases":2261,"primaryCompletion":605,"completion":606,"start":280,"enrollment":607,"conditions":2262,"interventions":2263},[87],[609],[45,485],{"nctId":623,"briefTitle":624,"status":102,"phases":2265,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":2266,"interventions":2267},[86,87],[293,294],[485,45,263],{"nctId":632,"briefTitle":633,"status":102,"phases":2269,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":2270,"interventions":2271},[87],[639],[485,45,641],{"nctId":750,"briefTitle":751,"status":102,"phases":2273,"primaryCompletion":753,"completion":335,"start":754,"enrollment":755,"conditions":2274,"interventions":2275},[87],[30],[45,485,748,490,489,486,487],{"nctId":759,"briefTitle":760,"status":102,"phases":2277,"primaryCompletion":762,"completion":763,"start":764,"enrollment":765,"conditions":2278,"interventions":2279},[87],[767],[45,485],{"nctId":781,"briefTitle":782,"status":102,"phases":2281,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":2282,"interventions":2283},[87],[788,789,790],[485,45,489,487,488,490,486],{"nctId":872,"briefTitle":873,"status":102,"phases":2285,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":2286,"interventions":2287},[87],[879],[485,45,881],{"trials":2289,"activeCount":13},[2290,2294],{"nctId":1005,"briefTitle":1006,"status":502,"phases":2291,"primaryCompletion":646,"completion":1008,"start":1009,"enrollment":1010,"conditions":2292,"interventions":2293},[88],[27,1012],[45,485,1014],{"nctId":1088,"briefTitle":1089,"status":502,"phases":2295,"primaryCompletion":1091,"completion":1091,"start":1092,"enrollment":347,"conditions":2296,"interventions":2297},[88],[30],[45,1095,485,512],{"trials":2299,"activeCount":13},[],{"trials":2301,"activeCount":13},[],{"intervention":834,"totalTrials":2303,"cells":2304},7,{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2313,"PHASE3":2327,"PHASE4":2341,"NA":2343},{"trials":2306,"activeCount":13},[],{"trials":2308,"activeCount":13},[2309],{"nctId":1207,"briefTitle":1208,"status":502,"phases":2310,"primaryCompletion":1210,"completion":1210,"start":595,"enrollment":472,"conditions":2311,"interventions":2312},[86],[1212],[1214,487,489,834],{"trials":2314,"activeCount":13},[2315,2319,2323],{"nctId":1704,"briefTitle":1705,"status":102,"phases":2316,"primaryCompletion":1707,"completion":1707,"start":1708,"enrollment":505,"conditions":2317,"interventions":2318},[87],[1055],[1711,834,78],{"nctId":828,"briefTitle":829,"status":502,"phases":2320,"primaryCompletion":300,"completion":300,"start":831,"enrollment":270,"conditions":2321,"interventions":2322},[87],[609],[568,45,834,835],{"nctId":858,"briefTitle":859,"status":102,"phases":2324,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":2325,"interventions":2326},[86,87],[866,867,868],[870,834,45,494,493],{"trials":2328,"activeCount":13},[2329,2333,2337],{"nctId":941,"briefTitle":942,"status":102,"phases":2330,"primaryCompletion":636,"completion":944,"start":945,"enrollment":946,"conditions":2331,"interventions":2332},[88],[27],[45,834],{"nctId":986,"briefTitle":987,"status":502,"phases":2334,"primaryCompletion":989,"completion":989,"start":990,"enrollment":991,"conditions":2335,"interventions":2336},[88],[993],[45,834,568],{"nctId":1108,"briefTitle":1109,"status":102,"phases":2338,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":2339,"interventions":2340},[88],[982],[45,487,834,835],{"trials":2342,"activeCount":13},[],{"trials":2344,"activeCount":13},[],{"intervention":568,"totalTrials":23,"cells":2346},{"EARLY_PHASE1":2347,"PHASE1":2349,"PHASE2":2364,"PHASE3":2374,"PHASE4":2384,"NA":2386},{"trials":2348,"activeCount":13},[],{"trials":2350,"activeCount":13},[2351,2360],{"nctId":2352,"briefTitle":2353,"status":102,"phases":2354,"primaryCompletion":2355,"completion":2355,"start":2356,"enrollment":9,"conditions":2357,"interventions":2359},"NCT04472650","Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults",[86],"2020-11-09","2020-07-23",[2358],"Tumor",[568,568],{"nctId":561,"briefTitle":562,"status":102,"phases":2361,"primaryCompletion":564,"completion":564,"start":402,"enrollment":565,"conditions":2362,"interventions":2363},[86],[25],[568,45],{"trials":2365,"activeCount":13},[2366,2370],{"nctId":828,"briefTitle":829,"status":502,"phases":2367,"primaryCompletion":300,"completion":300,"start":831,"enrollment":270,"conditions":2368,"interventions":2369},[87],[609],[568,45,834,835],{"nctId":928,"briefTitle":929,"status":102,"phases":2371,"primaryCompletion":931,"completion":931,"start":932,"enrollment":439,"conditions":2372,"interventions":2373},[86,87],[934,935],[568,45],{"trials":2375,"activeCount":13},[2376,2380],{"nctId":986,"briefTitle":987,"status":502,"phases":2377,"primaryCompletion":989,"completion":989,"start":990,"enrollment":991,"conditions":2378,"interventions":2379},[88],[993],[45,834,568],{"nctId":1027,"briefTitle":1028,"status":535,"phases":2381,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":13,"conditions":2382,"interventions":2383},[88],[813],[568,45],{"trials":2385,"activeCount":13},[],{"trials":2387,"activeCount":13},[],{"intervention":493,"totalTrials":937,"cells":2389},{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2398,"PHASE3":2408,"PHASE4":2418,"NA":2420},{"trials":2391,"activeCount":13},[],{"trials":2393,"activeCount":13},[2394],{"nctId":476,"briefTitle":477,"status":102,"phases":2395,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":2396,"interventions":2397},[86],[483],[485,45,486,487,488,489,490,491,492,493,494],{"trials":2399,"activeCount":13},[2400,2404],{"nctId":846,"briefTitle":847,"status":102,"phases":2401,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":2402,"interventions":2403},[87],[854],[45,490,856,493,494],{"nctId":858,"briefTitle":859,"status":102,"phases":2405,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":2406,"interventions":2407},[86,87],[866,867,868],[870,834,45,494,493],{"trials":2409,"activeCount":13},[2410,2414],{"nctId":974,"briefTitle":975,"status":102,"phases":2411,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":2412,"interventions":2413},[88],[982],[490,493,984,494,487,45],{"nctId":1016,"briefTitle":1017,"status":102,"phases":2415,"primaryCompletion":1019,"completion":1020,"start":1021,"enrollment":1022,"conditions":2416,"interventions":2417},[88],[1024],[45,490,493,494,692],{"trials":2419,"activeCount":13},[],{"trials":2421,"activeCount":13},[],{"intervention":2423,"totalTrials":28,"cells":2424},"BGB-3111",{"EARLY_PHASE1":2425,"PHASE1":2427,"PHASE2":2459,"PHASE3":2461,"PHASE4":2472,"NA":2474},{"trials":2426,"activeCount":13},[],{"trials":2428,"activeCount":13},[2429,2439,2448],{"nctId":2430,"briefTitle":2431,"status":102,"phases":2432,"primaryCompletion":2433,"completion":2433,"start":2434,"enrollment":2435,"conditions":2436,"interventions":2437},"NCT03432884","A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects",[86],"2018-04-16","2018-01-25",40,[16],[2423,2438],"Moxifloxacin",{"nctId":2440,"briefTitle":2441,"status":102,"phases":2442,"primaryCompletion":2443,"completion":2443,"start":2444,"enrollment":23,"conditions":2445,"interventions":2446},"NCT04163783","Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males",[86],"2017-04-18","2017-03-29",[16],[2447,2423],"[14C]-BGB-3111",{"nctId":2449,"briefTitle":2450,"status":102,"phases":2451,"primaryCompletion":2452,"completion":2453,"start":2454,"enrollment":2435,"conditions":2455,"interventions":2457},"NCT03301181","Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects",[86],"2017-11-07","2017-11-13","2017-09-18",[2456],"Healthy Volunteers: Asian, Non-Asian",[2423,2458,2423,1747],"Rifampin",{"trials":2460,"activeCount":13},[],{"trials":2462,"activeCount":13},[2463],{"nctId":2464,"briefTitle":2465,"status":102,"phases":2466,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":2470,"interventions":2471},"NCT03053440","A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)",[88],"2022-06-21","2017-01-25",201,[428],[2423,406],{"trials":2473,"activeCount":13},[],{"trials":2475,"activeCount":13},[],{"intervention":491,"totalTrials":419,"cells":2477},{"EARLY_PHASE1":2478,"PHASE1":2480,"PHASE2":2486,"PHASE3":2492,"PHASE4":2498,"NA":2500},{"trials":2479,"activeCount":13},[],{"trials":2481,"activeCount":13},[2482],{"nctId":476,"briefTitle":477,"status":102,"phases":2483,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":2484,"interventions":2485},[86],[483],[485,45,486,487,488,489,490,491,492,493,494],{"trials":2487,"activeCount":13},[2488],{"nctId":694,"briefTitle":695,"status":102,"phases":2489,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":2490,"interventions":2491},[87],[702],[45,487,704,491,486,490,489],{"trials":2493,"activeCount":13},[2494],{"nctId":1077,"briefTitle":1078,"status":102,"phases":2495,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":2496,"interventions":2497},[88],[1085],[45,490,489,491],{"trials":2499,"activeCount":13},[],{"trials":2501,"activeCount":13},[],{"intervention":512,"totalTrials":419,"cells":2503},{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2516,"PHASE3":2518,"PHASE4":2524,"NA":2526},{"trials":2505,"activeCount":13},[],{"trials":2507,"activeCount":13},[2508,2512],{"nctId":500,"briefTitle":501,"status":502,"phases":2509,"primaryCompletion":268,"completion":268,"start":504,"enrollment":505,"conditions":2510,"interventions":2511},[86],[507,19,508,509],[511,45,512],{"nctId":570,"briefTitle":571,"status":502,"phases":2513,"primaryCompletion":573,"completion":573,"start":44,"enrollment":574,"conditions":2514,"interventions":2515},[86],[19,509,520],[577,45,512],{"trials":2517,"activeCount":13},[],{"trials":2519,"activeCount":13},[2520],{"nctId":1088,"briefTitle":1089,"status":502,"phases":2521,"primaryCompletion":1091,"completion":1091,"start":1092,"enrollment":347,"conditions":2522,"interventions":2523},[88],[30],[45,1095,485,512],{"trials":2525,"activeCount":13},[],{"trials":2527,"activeCount":13},[],{"intervention":704,"totalTrials":587,"cells":2529},{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2534,"PHASE3":2540,"PHASE4":2546,"NA":2548},{"trials":2531,"activeCount":13},[],{"trials":2533,"activeCount":13},[],{"trials":2535,"activeCount":13},[2536],{"nctId":694,"briefTitle":695,"status":102,"phases":2537,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":2538,"interventions":2539},[87],[702],[45,487,704,491,486,490,489],{"trials":2541,"activeCount":13},[2542],{"nctId":1097,"briefTitle":1098,"status":102,"phases":2543,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":2544,"interventions":2545},[88],[1105],[45,704,490],{"trials":2547,"activeCount":13},[],{"trials":2549,"activeCount":13},[],{"intervention":406,"totalTrials":587,"cells":2551},{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2558,"PHASE4":2568,"NA":2570},{"trials":2553,"activeCount":13},[],{"trials":2555,"activeCount":13},[],{"trials":2557,"activeCount":13},[],{"trials":2559,"activeCount":13},[2560,2564],{"nctId":2464,"briefTitle":2465,"status":102,"phases":2561,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":2562,"interventions":2563},[88],[428],[2423,406],{"nctId":397,"briefTitle":398,"status":102,"phases":2565,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":2566,"interventions":2567},[88],[32,34],[40,406],{"trials":2569,"activeCount":13},[],{"trials":2571,"activeCount":13},[],{"intervention":835,"totalTrials":587,"cells":2573},{"EARLY_PHASE1":2574,"PHASE1":2576,"PHASE2":2578,"PHASE3":2584,"PHASE4":2590,"NA":2592},{"trials":2575,"activeCount":13},[],{"trials":2577,"activeCount":13},[],{"trials":2579,"activeCount":13},[2580],{"nctId":828,"briefTitle":829,"status":502,"phases":2581,"primaryCompletion":300,"completion":300,"start":831,"enrollment":270,"conditions":2582,"interventions":2583},[87],[609],[568,45,834,835],{"trials":2585,"activeCount":13},[2586],{"nctId":1108,"briefTitle":1109,"status":102,"phases":2587,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":1114,"conditions":2588,"interventions":2589},[88],[982],[45,487,834,835],{"trials":2591,"activeCount":13},[],{"trials":2593,"activeCount":13},[],{"intervention":959,"totalTrials":374,"cells":2595},{"EARLY_PHASE1":2596,"PHASE1":2598,"PHASE2":2600,"PHASE3":2602,"PHASE4":2608,"NA":2610},{"trials":2597,"activeCount":13},[],{"trials":2599,"activeCount":13},[],{"trials":2601,"activeCount":13},[],{"trials":2603,"activeCount":13},[2604],{"nctId":950,"briefTitle":951,"status":102,"phases":2605,"primaryCompletion":953,"completion":954,"start":955,"enrollment":956,"conditions":2606,"interventions":2607},[88],[599],[45,959],{"trials":2609,"activeCount":13},[],{"trials":2611,"activeCount":13},[],{"intervention":984,"totalTrials":374,"cells":2613},{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2618,"PHASE3":2620,"PHASE4":2626,"NA":2628},{"trials":2615,"activeCount":13},[],{"trials":2617,"activeCount":13},[],{"trials":2619,"activeCount":13},[],{"trials":2621,"activeCount":13},[2622],{"nctId":974,"briefTitle":975,"status":102,"phases":2623,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":2624,"interventions":2625},[88],[982],[490,493,984,494,487,45],{"trials":2627,"activeCount":13},[],{"trials":2629,"activeCount":13},[],{"intervention":1003,"totalTrials":374,"cells":2631},{"EARLY_PHASE1":2632,"PHASE1":2634,"PHASE2":2636,"PHASE3":2638,"PHASE4":2644,"NA":2646},{"trials":2633,"activeCount":13},[],{"trials":2635,"activeCount":13},[],{"trials":2637,"activeCount":13},[],{"trials":2639,"activeCount":13},[2640],{"nctId":996,"briefTitle":997,"status":502,"phases":2641,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":419,"conditions":2642,"interventions":2643},[88],[843],[45,1003],{"trials":2645,"activeCount":13},[],{"trials":2647,"activeCount":13},[],{"intervention":1014,"totalTrials":374,"cells":2649},{"EARLY_PHASE1":2650,"PHASE1":2652,"PHASE2":2654,"PHASE3":2656,"PHASE4":2662,"NA":2664},{"trials":2651,"activeCount":13},[],{"trials":2653,"activeCount":13},[],{"trials":2655,"activeCount":13},[],{"trials":2657,"activeCount":13},[2658],{"nctId":1005,"briefTitle":1006,"status":502,"phases":2659,"primaryCompletion":646,"completion":1008,"start":1009,"enrollment":1010,"conditions":2660,"interventions":2661},[88],[27,1012],[45,485,1014],{"trials":2663,"activeCount":13},[],{"trials":2665,"activeCount":13},[],{"intervention":1075,"totalTrials":374,"cells":2667},{"EARLY_PHASE1":2668,"PHASE1":2670,"PHASE2":2672,"PHASE3":2674,"PHASE4":2680,"NA":2682},{"trials":2669,"activeCount":13},[],{"trials":2671,"activeCount":13},[],{"trials":2673,"activeCount":13},[],{"trials":2675,"activeCount":13},[2676],{"nctId":1067,"briefTitle":1068,"status":102,"phases":2677,"primaryCompletion":1070,"completion":166,"start":1071,"enrollment":1072,"conditions":2678,"interventions":2679},[88],[1055],[45,487,1075,489],{"trials":2681,"activeCount":13},[],{"trials":2683,"activeCount":13},[],{"intervention":1095,"totalTrials":374,"cells":2685},{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2690,"PHASE3":2692,"PHASE4":2698,"NA":2700},{"trials":2687,"activeCount":13},[],{"trials":2689,"activeCount":13},[],{"trials":2691,"activeCount":13},[],{"trials":2693,"activeCount":13},[2694],{"nctId":1088,"briefTitle":1089,"status":502,"phases":2695,"primaryCompletion":1091,"completion":1091,"start":1092,"enrollment":347,"conditions":2696,"interventions":2697},[88],[30],[45,1095,485,512],{"trials":2699,"activeCount":13},[],{"trials":2701,"activeCount":13},[],{"intervention":748,"totalTrials":587,"cells":2703},{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2708,"PHASE3":2718,"PHASE4":2720,"NA":2722},{"trials":2705,"activeCount":13},[],{"trials":2707,"activeCount":13},[],{"trials":2709,"activeCount":13},[2710,2714],{"nctId":736,"briefTitle":737,"status":102,"phases":2711,"primaryCompletion":739,"completion":739,"start":740,"enrollment":741,"conditions":2712,"interventions":2713},[86,87],[743,744,745],[747,45,748],{"nctId":750,"briefTitle":751,"status":102,"phases":2715,"primaryCompletion":753,"completion":335,"start":754,"enrollment":755,"conditions":2716,"interventions":2717},[87],[30],[45,485,748,490,489,486,487],{"trials":2719,"activeCount":13},[],{"trials":2721,"activeCount":13},[],{"trials":2723,"activeCount":13},[],{"intervention":2725,"totalTrials":587,"cells":2726},"BGB-DXP593",{"EARLY_PHASE1":2727,"PHASE1":2729,"PHASE2":2740,"PHASE3":2752,"PHASE4":2754,"NA":2756},{"trials":2728,"activeCount":13},[],{"trials":2730,"activeCount":13},[2731],{"nctId":2732,"briefTitle":2733,"status":102,"phases":2734,"primaryCompletion":2735,"completion":2735,"start":2736,"enrollment":1375,"conditions":2737,"interventions":2738},"NCT04669262","BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants",[86],"2021-05-21","2020-12-09",[139],[2739,2725],"BGB-DXP604",{"trials":2741,"activeCount":13},[2742],{"nctId":2743,"briefTitle":2744,"status":102,"phases":2745,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":2748,"conditions":2749,"interventions":2751},"NCT04551898","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)",[87],"2021-05-25","2020-12-02",181,[2750],"Covid19",[2725],{"trials":2753,"activeCount":13},[],{"trials":2755,"activeCount":13},[],{"trials":2757,"activeCount":13},[],{"intervention":2759,"totalTrials":587,"cells":2760},"BGB-290",{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2775,"PHASE3":2787,"PHASE4":2789,"NA":2791},{"trials":2762,"activeCount":13},[],{"trials":2764,"activeCount":13},[2765],{"nctId":2766,"briefTitle":2767,"status":102,"phases":2768,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":2771,"conditions":2772,"interventions":2774},"NCT02361723","Phase 1a\u002F1b BGB-290 for Advanced Solid Tumors.",[86],"2019-09-03","2014-07-03",101,[2773],"For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment",[2759,2759,2759,2759,2759],{"trials":2776,"activeCount":13},[2777],{"nctId":2778,"briefTitle":2779,"status":102,"phases":2780,"primaryCompletion":2781,"completion":2782,"start":2783,"enrollment":2784,"conditions":2785,"interventions":2786},"NCT03575065","Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China",[87],"2020-10-09","2021-04-14","2018-06-22",88,[2017],[2759],{"trials":2788,"activeCount":13},[],{"trials":2790,"activeCount":13},[],{"trials":2792,"activeCount":13},[],{"intervention":817,"totalTrials":587,"cells":2794},{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2799,"PHASE3":2809,"PHASE4":2811,"NA":2813},{"trials":2796,"activeCount":13},[],{"trials":2798,"activeCount":13},[],{"trials":2800,"activeCount":13},[2801,2805],{"nctId":805,"briefTitle":806,"status":102,"phases":2802,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":2803,"interventions":2804},[87],[813,814,815],[817,45],{"nctId":908,"briefTitle":909,"status":102,"phases":2806,"primaryCompletion":911,"completion":912,"start":913,"enrollment":168,"conditions":2807,"interventions":2808},[87],[19],[916,45],{"trials":2810,"activeCount":13},[],{"trials":2812,"activeCount":13},[],{"trials":2814,"activeCount":13},[],{"intervention":2816,"totalTrials":587,"cells":2817},"BGB-A317",{"EARLY_PHASE1":2818,"PHASE1":2820,"PHASE2":2831,"PHASE3":2842,"PHASE4":2844,"NA":2846},{"trials":2819,"activeCount":13},[],{"trials":2821,"activeCount":13},[2822],{"nctId":2823,"briefTitle":2824,"status":102,"phases":2825,"primaryCompletion":2826,"completion":2826,"start":2827,"enrollment":2828,"conditions":2829,"interventions":2830},"NCT02407990","Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors",[86],"2020-08-12","2015-06-02",451,[507],[2816,2816],{"trials":2832,"activeCount":13},[2833],{"nctId":2834,"briefTitle":2835,"status":502,"phases":2836,"primaryCompletion":246,"completion":246,"start":2837,"enrollment":2838,"conditions":2839,"interventions":2840},"NCT03379259","Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors",[86,87],"2017-11-27",39,[25],[2841,2816],"BGB-A333",{"trials":2843,"activeCount":13},[],{"trials":2845,"activeCount":13},[],{"trials":2847,"activeCount":13},[],{"intervention":641,"totalTrials":374,"cells":2849},{"EARLY_PHASE1":2850,"PHASE1":2852,"PHASE2":2854,"PHASE3":2860,"PHASE4":2862,"NA":2864},{"trials":2851,"activeCount":13},[],{"trials":2853,"activeCount":13},[],{"trials":2855,"activeCount":13},[2856],{"nctId":632,"briefTitle":633,"status":102,"phases":2857,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":2858,"interventions":2859},[87],[639],[485,45,641],{"trials":2861,"activeCount":13},[],{"trials":2863,"activeCount":13},[],{"trials":2865,"activeCount":13},[],{"intervention":654,"totalTrials":374,"cells":2867},{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2878,"PHASE4":2880,"NA":2882},{"trials":2869,"activeCount":13},[],{"trials":2871,"activeCount":13},[],{"trials":2873,"activeCount":13},[2874],{"nctId":643,"briefTitle":644,"status":102,"phases":2875,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":2876,"interventions":2877},[87],[651,609,652],[55,45,654],{"trials":2879,"activeCount":13},[],{"trials":2881,"activeCount":13},[],{"trials":2883,"activeCount":13},[],{"intervention":1711,"totalTrials":374,"cells":2885},{"EARLY_PHASE1":2886,"PHASE1":2888,"PHASE2":2890,"PHASE3":2896,"PHASE4":2898,"NA":2900},{"trials":2887,"activeCount":13},[],{"trials":2889,"activeCount":13},[],{"trials":2891,"activeCount":13},[2892],{"nctId":1704,"briefTitle":1705,"status":102,"phases":2893,"primaryCompletion":1707,"completion":1707,"start":1708,"enrollment":505,"conditions":2894,"interventions":2895},[87],[1055],[1711,834,78],{"trials":2897,"activeCount":13},[],{"trials":2899,"activeCount":13},[],{"trials":2901,"activeCount":13},[],{"intervention":734,"totalTrials":374,"cells":2903},{"EARLY_PHASE1":2904,"PHASE1":2906,"PHASE2":2908,"PHASE3":2914,"PHASE4":2916,"NA":2918},{"trials":2905,"activeCount":13},[],{"trials":2907,"activeCount":13},[],{"trials":2909,"activeCount":13},[2910],{"nctId":726,"briefTitle":727,"status":102,"phases":2911,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":2912,"interventions":2913},[87],[25],[45,734],{"trials":2915,"activeCount":13},[],{"trials":2917,"activeCount":13},[],{"trials":2919,"activeCount":13},[],{"intervention":747,"totalTrials":374,"cells":2921},{"EARLY_PHASE1":2922,"PHASE1":2924,"PHASE2":2926,"PHASE3":2932,"PHASE4":2934,"NA":2936},{"trials":2923,"activeCount":13},[],{"trials":2925,"activeCount":13},[],{"trials":2927,"activeCount":13},[2928],{"nctId":736,"briefTitle":737,"status":102,"phases":2929,"primaryCompletion":739,"completion":739,"start":740,"enrollment":741,"conditions":2930,"interventions":2931},[86,87],[743,744,745],[747,45,748],{"trials":2933,"activeCount":13},[],{"trials":2935,"activeCount":13},[],{"trials":2937,"activeCount":13},[],{"intervention":856,"totalTrials":374,"cells":2939},{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2944,"PHASE3":2950,"PHASE4":2952,"NA":2954},{"trials":2941,"activeCount":13},[],{"trials":2943,"activeCount":13},[],{"trials":2945,"activeCount":13},[2946],{"nctId":846,"briefTitle":847,"status":102,"phases":2947,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":2948,"interventions":2949},[87],[854],[45,490,856,493,494],{"trials":2951,"activeCount":13},[],{"trials":2953,"activeCount":13},[],{"trials":2955,"activeCount":13},[],{"intervention":870,"totalTrials":374,"cells":2957},{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2962,"PHASE3":2968,"PHASE4":2970,"NA":2972},{"trials":2959,"activeCount":13},[],{"trials":2961,"activeCount":13},[],{"trials":2963,"activeCount":13},[2964],{"nctId":858,"briefTitle":859,"status":102,"phases":2965,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":2966,"interventions":2967},[86,87],[866,867,868],[870,834,45,494,493],{"trials":2969,"activeCount":13},[],{"trials":2971,"activeCount":13},[],{"trials":2973,"activeCount":13},[],{"intervention":2841,"totalTrials":374,"cells":2975},{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2980,"PHASE3":2986,"PHASE4":2988,"NA":2990},{"trials":2977,"activeCount":13},[],{"trials":2979,"activeCount":13},[],{"trials":2981,"activeCount":13},[2982],{"nctId":2834,"briefTitle":2835,"status":502,"phases":2983,"primaryCompletion":246,"completion":246,"start":2837,"enrollment":2838,"conditions":2984,"interventions":2985},[86,87],[25],[2841,2816],{"trials":2987,"activeCount":13},[],{"trials":2989,"activeCount":13},[],{"trials":2991,"activeCount":13},[],{"intervention":352,"totalTrials":374,"cells":2993},{"EARLY_PHASE1":2994,"PHASE1":2996,"PHASE2":2998,"PHASE3":3004,"PHASE4":3006,"NA":3008},{"trials":2995,"activeCount":13},[],{"trials":2997,"activeCount":13},[],{"trials":2999,"activeCount":13},[3000],{"nctId":342,"briefTitle":343,"status":102,"phases":3001,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":3002,"interventions":3003},[87],[349,350],[40,352],{"trials":3005,"activeCount":13},[],{"trials":3007,"activeCount":13},[],{"trials":3009,"activeCount":13},[],{"intervention":881,"totalTrials":374,"cells":3011},{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3016,"PHASE3":3022,"PHASE4":3024,"NA":3026},{"trials":3013,"activeCount":13},[],{"trials":3015,"activeCount":13},[],{"trials":3017,"activeCount":13},[3018],{"nctId":872,"briefTitle":873,"status":102,"phases":3019,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":3020,"interventions":3021},[87],[879],[485,45,881],{"trials":3023,"activeCount":13},[],{"trials":3025,"activeCount":13},[],{"trials":3027,"activeCount":13},[],{"intervention":373,"totalTrials":374,"cells":3029},{"EARLY_PHASE1":3030,"PHASE1":3032,"PHASE2":3034,"PHASE3":3040,"PHASE4":3042,"NA":3044},{"trials":3031,"activeCount":13},[],{"trials":3033,"activeCount":13},[],{"trials":3035,"activeCount":13},[3036],{"nctId":364,"briefTitle":365,"status":102,"phases":3037,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":3038,"interventions":3039},[86,87],[32,34,260,22,273,371,19],[373,40,45],{"trials":3041,"activeCount":13},[],{"trials":3043,"activeCount":13},[],{"trials":3045,"activeCount":13},[],{"intervention":1431,"totalTrials":374,"cells":3047},{"EARLY_PHASE1":3048,"PHASE1":3050,"PHASE2":3052,"PHASE3":3058,"PHASE4":3060,"NA":3062},{"trials":3049,"activeCount":13},[],{"trials":3051,"activeCount":13},[],{"trials":3053,"activeCount":13},[3054],{"nctId":1422,"briefTitle":1423,"status":102,"phases":3055,"primaryCompletion":1425,"completion":1425,"start":1426,"enrollment":1427,"conditions":3056,"interventions":3057},[86,87],[1429],[83,1431],{"trials":3059,"activeCount":13},[],{"trials":3061,"activeCount":13},[],{"trials":3063,"activeCount":13},[],{"intervention":1747,"totalTrials":28,"cells":3065},{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3086,"PHASE3":3088,"PHASE4":3090,"NA":3092},{"trials":3067,"activeCount":13},[],{"trials":3069,"activeCount":13},[3070,3074,3078,3082],{"nctId":1906,"briefTitle":1907,"status":102,"phases":3071,"primaryCompletion":1909,"completion":1910,"start":1911,"enrollment":852,"conditions":3072,"interventions":3073},[86],[1913],[1748,1747,1899],{"nctId":1370,"briefTitle":1371,"status":102,"phases":3075,"primaryCompletion":1373,"completion":1374,"start":1041,"enrollment":1375,"conditions":3076,"interventions":3077},[86],[520],[1378,1379,1380,1381,1382],{"nctId":1740,"briefTitle":1741,"status":102,"phases":3079,"primaryCompletion":999,"completion":999,"start":1743,"enrollment":1744,"conditions":3080,"interventions":3081},[86],[16],[1723,1747,1748],{"nctId":2449,"briefTitle":2450,"status":102,"phases":3083,"primaryCompletion":2452,"completion":2453,"start":2454,"enrollment":2435,"conditions":3084,"interventions":3085},[86],[2456],[2423,2458,2423,1747],{"trials":3087,"activeCount":13},[],{"trials":3089,"activeCount":13},[],{"trials":3091,"activeCount":13},[],{"trials":3093,"activeCount":13},[],{"intervention":3095,"totalTrials":587,"cells":3096},"BGB-23339",{"EARLY_PHASE1":3097,"PHASE1":3099,"PHASE2":3119,"PHASE3":3121,"PHASE4":3123,"NA":3125},{"trials":3098,"activeCount":13},[],{"trials":3100,"activeCount":13},[3101,3109],{"nctId":3102,"briefTitle":3103,"status":535,"phases":3104,"primaryCompletion":3105,"completion":3105,"start":3106,"enrollment":13,"conditions":3107,"interventions":3108},"NCT05387668","Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects",[86],"2022-10-17","2022-02-17",[16],[3095],{"nctId":3110,"briefTitle":3111,"status":102,"phases":3112,"primaryCompletion":3113,"completion":3114,"start":3115,"enrollment":3116,"conditions":3117,"interventions":3118},"NCT05093270","First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants",[86],"2022-09-15","2022-12-26","2021-11-15",92,[1913],[3095],{"trials":3120,"activeCount":13},[],{"trials":3122,"activeCount":13},[],{"trials":3124,"activeCount":13},[],{"trials":3126,"activeCount":13},[],{"intervention":1748,"totalTrials":587,"cells":3128},{"EARLY_PHASE1":3129,"PHASE1":3131,"PHASE2":3141,"PHASE3":3143,"PHASE4":3145,"NA":3147},{"trials":3130,"activeCount":13},[],{"trials":3132,"activeCount":13},[3133,3137],{"nctId":1906,"briefTitle":1907,"status":102,"phases":3134,"primaryCompletion":1909,"completion":1910,"start":1911,"enrollment":852,"conditions":3135,"interventions":3136},[86],[1913],[1748,1747,1899],{"nctId":1740,"briefTitle":1741,"status":102,"phases":3138,"primaryCompletion":999,"completion":999,"start":1743,"enrollment":1744,"conditions":3139,"interventions":3140},[86],[16],[1723,1747,1748],{"trials":3142,"activeCount":13},[],{"trials":3144,"activeCount":13},[],{"trials":3146,"activeCount":13},[],{"trials":3148,"activeCount":13},[],{"intervention":522,"totalTrials":587,"cells":3150},{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3163,"PHASE3":3165,"PHASE4":3167,"NA":3169},{"trials":3152,"activeCount":13},[],{"trials":3154,"activeCount":13},[3155,3159],{"nctId":514,"briefTitle":515,"status":502,"phases":3156,"primaryCompletion":517,"completion":517,"start":518,"enrollment":214,"conditions":3157,"interventions":3158},[86],[520],[522,45],{"nctId":533,"briefTitle":534,"status":535,"phases":3160,"primaryCompletion":537,"completion":538,"start":539,"enrollment":13,"conditions":3161,"interventions":3162},[86],[541],[522,45],{"trials":3164,"activeCount":13},[],{"trials":3166,"activeCount":13},[],{"trials":3168,"activeCount":13},[],{"trials":3170,"activeCount":13},[],{"intervention":3172,"totalTrials":587,"cells":3173},"BGB-283",{"EARLY_PHASE1":3174,"PHASE1":3176,"PHASE2":3197,"PHASE3":3199,"PHASE4":3201,"NA":3203},{"trials":3175,"activeCount":13},[],{"trials":3177,"activeCount":13},[3178,3187],{"nctId":3179,"briefTitle":3180,"status":102,"phases":3181,"primaryCompletion":3182,"completion":3182,"start":3183,"enrollment":3184,"conditions":3185,"interventions":3186},"NCT02610361","Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors",[86],"2017-10","2013-11-20",131,[541],[3172],{"nctId":3188,"briefTitle":3189,"status":102,"phases":3190,"primaryCompletion":3191,"completion":3192,"start":3193,"enrollment":3194,"conditions":3195,"interventions":3196},"NCT03641586","The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor",[86],"2016-12-06","2019-03-07","2015-10-12",42,[541],[3172],{"trials":3198,"activeCount":13},[],{"trials":3200,"activeCount":13},[],{"trials":3202,"activeCount":13},[],{"trials":3204,"activeCount":13},[],{"intervention":1381,"totalTrials":587,"cells":3206},{"EARLY_PHASE1":3207,"PHASE1":3209,"PHASE2":3219,"PHASE3":3221,"PHASE4":3223,"NA":3225},{"trials":3208,"activeCount":13},[],{"trials":3210,"activeCount":13},[3211,3215],{"nctId":1370,"briefTitle":1371,"status":102,"phases":3212,"primaryCompletion":1373,"completion":1374,"start":1041,"enrollment":1375,"conditions":3213,"interventions":3214},[86],[520],[1378,1379,1380,1381,1382],{"nctId":2449,"briefTitle":2450,"status":102,"phases":3216,"primaryCompletion":2452,"completion":2453,"start":2454,"enrollment":2435,"conditions":3217,"interventions":3218},[86],[2456],[2423,2458,2423,1747],{"trials":3220,"activeCount":13},[],{"trials":3222,"activeCount":13},[],{"trials":3224,"activeCount":13},[],{"trials":3226,"activeCount":13},[],{"intervention":3228,"totalTrials":374,"cells":3229},"BGB DXP593",{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3241,"PHASE3":3243,"PHASE4":3245,"NA":3247},{"trials":3231,"activeCount":13},[],{"trials":3233,"activeCount":13},[3234],{"nctId":3235,"briefTitle":3236,"status":102,"phases":3237,"primaryCompletion":3238,"completion":3238,"start":246,"enrollment":159,"conditions":3239,"interventions":3240},"NCT04532294","Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2\u002FCOVID-19) Neutralizing Antibody in Healthy Participants",[86],"2021-02-13",[2750],[3228],{"trials":3242,"activeCount":13},[],{"trials":3244,"activeCount":13},[],{"trials":3246,"activeCount":13},[],{"trials":3248,"activeCount":13},[],{"intervention":492,"totalTrials":374,"cells":3250},{"EARLY_PHASE1":3251,"PHASE1":3253,"PHASE2":3259,"PHASE3":3261,"PHASE4":3263,"NA":3265},{"trials":3252,"activeCount":13},[],{"trials":3254,"activeCount":13},[3255],{"nctId":476,"briefTitle":477,"status":102,"phases":3256,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":3257,"interventions":3258},[86],[483],[485,45,486,487,488,489,490,491,492,493,494],{"trials":3260,"activeCount":13},[],{"trials":3262,"activeCount":13},[],{"trials":3264,"activeCount":13},[],{"trials":3266,"activeCount":13},[],{"intervention":3268,"totalTrials":374,"cells":3269},"Dinutuximab Beta",{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3283,"PHASE3":3285,"PHASE4":3287,"NA":3289},{"trials":3271,"activeCount":13},[],{"trials":3273,"activeCount":13},[3274],{"nctId":3275,"briefTitle":3276,"status":102,"phases":3277,"primaryCompletion":3278,"completion":3278,"start":127,"enrollment":20,"conditions":3279,"interventions":3281},"NCT05373901","Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma",[86],"2023-06-29",[3280],"High-risk Neuroblastoma",[3268,3282],"13-cis-Retinoic Acid",{"trials":3284,"activeCount":13},[],{"trials":3286,"activeCount":13},[],{"trials":3288,"activeCount":13},[],{"trials":3290,"activeCount":13},[],{"intervention":3282,"totalTrials":374,"cells":3292},{"EARLY_PHASE1":3293,"PHASE1":3295,"PHASE2":3301,"PHASE3":3303,"PHASE4":3305,"NA":3307},{"trials":3294,"activeCount":13},[],{"trials":3296,"activeCount":13},[3297],{"nctId":3275,"briefTitle":3276,"status":102,"phases":3298,"primaryCompletion":3278,"completion":3278,"start":127,"enrollment":20,"conditions":3299,"interventions":3300},[86],[3280],[3268,3282],{"trials":3302,"activeCount":13},[],{"trials":3304,"activeCount":13},[],{"trials":3306,"activeCount":13},[],{"trials":3308,"activeCount":13},[],{"intervention":511,"totalTrials":374,"cells":3310},{"EARLY_PHASE1":3311,"PHASE1":3313,"PHASE2":3319,"PHASE3":3321,"PHASE4":3323,"NA":3325},{"trials":3312,"activeCount":13},[],{"trials":3314,"activeCount":13},[3315],{"nctId":500,"briefTitle":501,"status":502,"phases":3316,"primaryCompletion":268,"completion":268,"start":504,"enrollment":505,"conditions":3317,"interventions":3318},[86],[507,19,508,509],[511,45,512],{"trials":3320,"activeCount":13},[],{"trials":3322,"activeCount":13},[],{"trials":3324,"activeCount":13},[],{"trials":3326,"activeCount":13},[],{"intervention":142,"totalTrials":374,"cells":3328},{"EARLY_PHASE1":3329,"PHASE1":3331,"PHASE2":3337,"PHASE3":3339,"PHASE4":3341,"NA":3343},{"trials":3330,"activeCount":13},[],{"trials":3332,"activeCount":13},[3333],{"nctId":132,"briefTitle":133,"status":102,"phases":3334,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":3335,"interventions":3336},[86],[139,140],[40,142],{"trials":3338,"activeCount":13},[],{"trials":3340,"activeCount":13},[],{"trials":3342,"activeCount":13},[],{"trials":3344,"activeCount":13},[],{"intervention":2438,"totalTrials":374,"cells":3346},{"EARLY_PHASE1":3347,"PHASE1":3349,"PHASE2":3355,"PHASE3":3357,"PHASE4":3359,"NA":3361},{"trials":3348,"activeCount":13},[],{"trials":3350,"activeCount":13},[3351],{"nctId":2430,"briefTitle":2431,"status":102,"phases":3352,"primaryCompletion":2433,"completion":2433,"start":2434,"enrollment":2435,"conditions":3353,"interventions":3354},[86],[16],[2423,2438],{"trials":3356,"activeCount":13},[],{"trials":3358,"activeCount":13},[],{"trials":3360,"activeCount":13},[],{"trials":3362,"activeCount":13},[],{"intervention":191,"totalTrials":374,"cells":3364},{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3373,"PHASE3":3375,"PHASE4":3377,"NA":3379},{"trials":3366,"activeCount":13},[],{"trials":3368,"activeCount":13},[3369],{"nctId":183,"briefTitle":184,"status":102,"phases":3370,"primaryCompletion":186,"completion":186,"start":187,"enrollment":9,"conditions":3371,"interventions":3372},[86],[189],[40,191,192,193,194],{"trials":3374,"activeCount":13},[],{"trials":3376,"activeCount":13},[],{"trials":3378,"activeCount":13},[],{"trials":3380,"activeCount":13},[],{"intervention":192,"totalTrials":374,"cells":3382},{"EARLY_PHASE1":3383,"PHASE1":3385,"PHASE2":3391,"PHASE3":3393,"PHASE4":3395,"NA":3397},{"trials":3384,"activeCount":13},[],{"trials":3386,"activeCount":13},[3387],{"nctId":183,"briefTitle":184,"status":102,"phases":3388,"primaryCompletion":186,"completion":186,"start":187,"enrollment":9,"conditions":3389,"interventions":3390},[86],[189],[40,191,192,193,194],{"trials":3392,"activeCount":13},[],{"trials":3394,"activeCount":13},[],{"trials":3396,"activeCount":13},[],{"trials":3398,"activeCount":13},[],{"intervention":193,"totalTrials":374,"cells":3400},{"EARLY_PHASE1":3401,"PHASE1":3403,"PHASE2":3409,"PHASE3":3411,"PHASE4":3413,"NA":3415},{"trials":3402,"activeCount":13},[],{"trials":3404,"activeCount":13},[3405],{"nctId":183,"briefTitle":184,"status":102,"phases":3406,"primaryCompletion":186,"completion":186,"start":187,"enrollment":9,"conditions":3407,"interventions":3408},[86],[189],[40,191,192,193,194],{"trials":3410,"activeCount":13},[],{"trials":3412,"activeCount":13},[],{"trials":3414,"activeCount":13},[],{"trials":3416,"activeCount":13},[],{"intervention":194,"totalTrials":374,"cells":3418},{"EARLY_PHASE1":3419,"PHASE1":3421,"PHASE2":3427,"PHASE3":3429,"PHASE4":3431,"NA":3433},{"trials":3420,"activeCount":13},[],{"trials":3422,"activeCount":13},[3423],{"nctId":183,"briefTitle":184,"status":102,"phases":3424,"primaryCompletion":186,"completion":186,"start":187,"enrollment":9,"conditions":3425,"interventions":3426},[86],[189],[40,191,192,193,194],{"trials":3428,"activeCount":13},[],{"trials":3430,"activeCount":13},[],{"trials":3432,"activeCount":13},[],{"trials":3434,"activeCount":13},[],{"intervention":3436,"totalTrials":374,"cells":3437},"Lifirafenib",{"EARLY_PHASE1":3438,"PHASE1":3440,"PHASE2":3452,"PHASE3":3454,"PHASE4":3456,"NA":3458},{"trials":3439,"activeCount":13},[],{"trials":3441,"activeCount":13},[3442],{"nctId":3443,"briefTitle":3444,"status":102,"phases":3445,"primaryCompletion":3446,"completion":3447,"start":3448,"enrollment":225,"conditions":3449,"interventions":3450},"NCT03905148","Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors",[86],"2024-10-09","2025-10-23","2019-05-01",[1212],[3436,3451],"mirdametinib",{"trials":3453,"activeCount":13},[],{"trials":3455,"activeCount":13},[],{"trials":3457,"activeCount":13},[],{"trials":3459,"activeCount":13},[],{"intervention":3451,"totalTrials":374,"cells":3461},{"EARLY_PHASE1":3462,"PHASE1":3464,"PHASE2":3470,"PHASE3":3472,"PHASE4":3474,"NA":3476},{"trials":3463,"activeCount":13},[],{"trials":3465,"activeCount":13},[3466],{"nctId":3443,"briefTitle":3444,"status":102,"phases":3467,"primaryCompletion":3446,"completion":3447,"start":3448,"enrollment":225,"conditions":3468,"interventions":3469},[86],[1212],[3436,3451],{"trials":3471,"activeCount":13},[],{"trials":3473,"activeCount":13},[],{"trials":3475,"activeCount":13},[],{"trials":3477,"activeCount":13},[],{"intervention":531,"totalTrials":374,"cells":3479},{"EARLY_PHASE1":3480,"PHASE1":3482,"PHASE2":3488,"PHASE3":3490,"PHASE4":3492,"NA":3494},{"trials":3481,"activeCount":13},[],{"trials":3483,"activeCount":13},[3484],{"nctId":524,"briefTitle":525,"status":502,"phases":3485,"primaryCompletion":527,"completion":527,"start":528,"enrollment":149,"conditions":3486,"interventions":3487},[86],[25],[531,45],{"trials":3489,"activeCount":13},[],{"trials":3491,"activeCount":13},[],{"trials":3493,"activeCount":13},[],{"trials":3495,"activeCount":13},[],{"intervention":2739,"totalTrials":374,"cells":3497},{"EARLY_PHASE1":3498,"PHASE1":3500,"PHASE2":3506,"PHASE3":3508,"PHASE4":3510,"NA":3512},{"trials":3499,"activeCount":13},[],{"trials":3501,"activeCount":13},[3502],{"nctId":2732,"briefTitle":2733,"status":102,"phases":3503,"primaryCompletion":2735,"completion":2735,"start":2736,"enrollment":1375,"conditions":3504,"interventions":3505},[86],[139],[2739,2725],{"trials":3507,"activeCount":13},[],{"trials":3509,"activeCount":13},[],{"trials":3511,"activeCount":13},[],{"trials":3513,"activeCount":13},[],{"intervention":1368,"totalTrials":374,"cells":3515},{"EARLY_PHASE1":3516,"PHASE1":3518,"PHASE2":3524,"PHASE3":3526,"PHASE4":3528,"NA":3530},{"trials":3517,"activeCount":13},[],{"trials":3519,"activeCount":13},[3520],{"nctId":1359,"briefTitle":1360,"status":102,"phases":3521,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":3522,"interventions":3523},[86],[1366],[83,1368],{"trials":3525,"activeCount":13},[],{"trials":3527,"activeCount":13},[],{"trials":3529,"activeCount":13},[],{"trials":3531,"activeCount":13},[],{"intervention":3533,"totalTrials":374,"cells":3534},"[14C]-pamiparib",{"EARLY_PHASE1":3535,"PHASE1":3537,"PHASE2":3547,"PHASE3":3549,"PHASE4":3551,"NA":3553},{"trials":3536,"activeCount":13},[],{"trials":3538,"activeCount":13},[3539],{"nctId":3540,"briefTitle":3541,"status":102,"phases":3542,"primaryCompletion":3543,"completion":3544,"start":1041,"enrollment":28,"conditions":3545,"interventions":3546},"NCT03991494","Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer",[86],"2019-10-21","2020-08-05",[25],[3533],{"trials":3548,"activeCount":13},[],{"trials":3550,"activeCount":13},[],{"trials":3552,"activeCount":13},[],{"trials":3554,"activeCount":13},[],{"intervention":3556,"totalTrials":374,"cells":3557},"[14C]-BGB-16673",{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3569,"PHASE3":3571,"PHASE4":3573,"NA":3575},{"trials":3559,"activeCount":13},[],{"trials":3561,"activeCount":13},[3562],{"nctId":3563,"briefTitle":3564,"status":102,"phases":3565,"primaryCompletion":3566,"completion":3566,"start":49,"enrollment":20,"conditions":3567,"interventions":3568},"NCT06776679","A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants",[86],"2025-03-27",[16],[3556],{"trials":3570,"activeCount":13},[],{"trials":3572,"activeCount":13},[],{"trials":3574,"activeCount":13},[],{"trials":3576,"activeCount":13},[],{"intervention":1378,"totalTrials":374,"cells":3578},{"EARLY_PHASE1":3579,"PHASE1":3581,"PHASE2":3587,"PHASE3":3589,"PHASE4":3591,"NA":3593},{"trials":3580,"activeCount":13},[],{"trials":3582,"activeCount":13},[3583],{"nctId":1370,"briefTitle":1371,"status":102,"phases":3584,"primaryCompletion":1373,"completion":1374,"start":1041,"enrollment":1375,"conditions":3585,"interventions":3586},[86],[520],[1378,1379,1380,1381,1382],{"trials":3588,"activeCount":13},[],{"trials":3590,"activeCount":13},[],{"trials":3592,"activeCount":13},[],{"trials":3594,"activeCount":13},[],{"intervention":1379,"totalTrials":374,"cells":3596},{"EARLY_PHASE1":3597,"PHASE1":3599,"PHASE2":3605,"PHASE3":3607,"PHASE4":3609,"NA":3611},{"trials":3598,"activeCount":13},[],{"trials":3600,"activeCount":13},[3601],{"nctId":1370,"briefTitle":1371,"status":102,"phases":3602,"primaryCompletion":1373,"completion":1374,"start":1041,"enrollment":1375,"conditions":3603,"interventions":3604},[86],[520],[1378,1379,1380,1381,1382],{"trials":3606,"activeCount":13},[],{"trials":3608,"activeCount":13},[],{"trials":3610,"activeCount":13},[],{"trials":3612,"activeCount":13},[],{"intervention":2447,"totalTrials":374,"cells":3614},{"EARLY_PHASE1":3615,"PHASE1":3617,"PHASE2":3623,"PHASE3":3625,"PHASE4":3627,"NA":3629},{"trials":3616,"activeCount":13},[],{"trials":3618,"activeCount":13},[3619],{"nctId":2440,"briefTitle":2441,"status":102,"phases":3620,"primaryCompletion":2443,"completion":2443,"start":2444,"enrollment":23,"conditions":3621,"interventions":3622},[86],[16],[2447,2423],{"trials":3624,"activeCount":13},[],{"trials":3626,"activeCount":13},[],{"trials":3628,"activeCount":13},[],{"trials":3630,"activeCount":13},[],{"intervention":3632,"totalTrials":374,"cells":3633},"[14C]-BGB-11417",{"EARLY_PHASE1":3634,"PHASE1":3636,"PHASE2":3646,"PHASE3":3648,"PHASE4":3650,"NA":3652},{"trials":3635,"activeCount":13},[],{"trials":3637,"activeCount":13},[3638],{"nctId":3639,"briefTitle":3640,"status":102,"phases":3641,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":23,"conditions":3644,"interventions":3645},"NCT05844111","A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417",[86],"2023-06-18","2023-05-22",[16],[3632],{"trials":3647,"activeCount":13},[],{"trials":3649,"activeCount":13},[],{"trials":3651,"activeCount":13},[],{"trials":3653,"activeCount":13},[],{"intervention":1214,"totalTrials":374,"cells":3655},{"EARLY_PHASE1":3656,"PHASE1":3658,"PHASE2":3664,"PHASE3":3666,"PHASE4":3668,"NA":3670},{"trials":3657,"activeCount":13},[],{"trials":3659,"activeCount":13},[3660],{"nctId":1207,"briefTitle":1208,"status":502,"phases":3661,"primaryCompletion":1210,"completion":1210,"start":595,"enrollment":472,"conditions":3662,"interventions":3663},[86],[1212],[1214,487,489,834],{"trials":3665,"activeCount":13},[],{"trials":3667,"activeCount":13},[],{"trials":3669,"activeCount":13},[],{"trials":3671,"activeCount":13},[],{"intervention":3673,"totalTrials":374,"cells":3674},"BGB-3111 and Drug Cocktail",{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3687,"PHASE3":3689,"PHASE4":3691,"NA":3693},{"trials":3676,"activeCount":13},[],{"trials":3678,"activeCount":13},[3679],{"nctId":3680,"briefTitle":3681,"status":102,"phases":3682,"primaryCompletion":3683,"completion":3684,"start":3683,"enrollment":159,"conditions":3685,"interventions":3686},"NCT03561298","A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects",[86],"2018-06-07","2018-07-02",[2092],[3673],{"trials":3688,"activeCount":13},[],{"trials":3690,"activeCount":13},[],{"trials":3692,"activeCount":13},[],{"trials":3694,"activeCount":13},[],{"intervention":577,"totalTrials":374,"cells":3696},{"EARLY_PHASE1":3697,"PHASE1":3699,"PHASE2":3705,"PHASE3":3707,"PHASE4":3709,"NA":3711},{"trials":3698,"activeCount":13},[],{"trials":3700,"activeCount":13},[3701],{"nctId":570,"briefTitle":571,"status":502,"phases":3702,"primaryCompletion":573,"completion":573,"start":44,"enrollment":574,"conditions":3703,"interventions":3704},[86],[19,509,520],[577,45,512],{"trials":3706,"activeCount":13},[],{"trials":3708,"activeCount":13},[],{"trials":3710,"activeCount":13},[],{"trials":3712,"activeCount":13},[]]